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Acronyms
AMPs Antimicrobial peptides.
AS Alanine scanning.
CAS Computational Alanine Scanning.
CG Coarse grain.
EBOV Ebola Virus.
ED Essential Dynamics.
IFN interferon.
KPNA Karyopherin .
MARV Marburg Virus.
MD Molecular Dynamics.
MM-PBSA Molecular Mechanics-Poisson Boltzmann Sur-
face Area.
NP Nucleoprotein.
PPIs Protein-protein interactions.
RDF Radial Distribution Function.
RMSD Root Mean Square Deviation.
RMSF Root Mean Square Fluctuation.
SDF Solvent Density Function.
VP24 Viral Protein 24.
VP35 Viral Protein 35.
Thesis Overview
Computer science has grown fast in the last few decades and it is going to keep
growing. Every year we witness the birth of new softwares, hardwares, OS allowing
us to have more and more powerful computers. In many fields of science such as
chemistry, physics and biology the theoretical simulation can help shedding light on
systems, processes, reactions that are not clear yet. On one hand, computer simu-
lations can help understanding empirical evidences or the mechanism of a reaction,
on the other hand simulations can be performed in conditions that could be difficult
(or impossible) to have in an actual laboratory. Moreover, simulations are particu-
larly useful in drug design and molecular modeling. Understanding interactions at
atomistic level can help to design a potential binder or inhibitor, and thus to avoid
experimental tests on a number of molecules.
In this PhD thesis various computational methods are employed, in order to study
different biological systems.
The first part of the thesis focuses on the modeling of Ebola virus inhibitors, study-
ing two of the seven viral proteins coded by Ebola genome: Viral Protein 24 and
Viral Protein 35.
 Chapter 2 deals with the interactions between known inhibitors of Viral Pro-
tein 35 and the protein itself. Ebola virus Viral Protein 35 carries out multiple
functions necessary for virus replication and infection, in particular interfering
with interferon-= signaling. Recently, this protein has been crystallized in
complex with small organic molecules able to inhibit its interaction with viral
nucleoprotein, thus reducing Ebola infections of cultured cells. In this chapter
we study the binding mechanism of these inhibitors both from the energetic
and conformational point of view, identifying a set of hot spots common to
all the molecules and detecting interesting collective motion of the protein in
complex with the ligands.
 In Chapter 3 we study the protein-protein interaction involving Viral Protein
24 and Karyopherin, responsible for the inhibition of the immune response
of the host organism. Modeling the VP24–Karyopherin complex allow us to
identify the amino acid residues responsible for protein–protein binding and
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lead us to the identification of a nonapeptide with VP24 binding potential.
Subsequently we assay the ability of this peptide to actually bind VP24 in
solution using Saturation Transfer Difference NMR and Circular Dichroism.
Finally we compare experimental and molecular modeling data concerning
the VP24–peptide complex and we discuss putative peptide binding sites and
modes.
 Chapter 4 focuses on the analysis of VP24 pockets. It is known that inhibitors
and drugs usually bind in clefts or pockets on the surface of the protein.
Moreover, transient pockets are likely to be found on protein surface due to
its dynamic character. In this chapter we carry out pocket analysis on VP24
crystallographic structure. Furthermore we perform molecular dynamics simu-
lations in water and more apolar solvents in order to identify transient pockets
and to study the evolution and properties of the pockets already present in
the crystallographic structure. Once we identify the best pocket we proceed
performing a virtual screening of a number of compounds, finding molecules
that could be able to bind at the interface with Karyopherin, inhibiting the
protein-protein complex formation.
 Chapter 5 handles the behavior of VP24 in presence of osmolytes. We study
VP24 in different solutions of either osmoprotectants or denaturants at dif-
ferent temperatures, in order to rationalize the effect of the osmolytes on this
protein. The subject of this chapter is not directly related to the modeling
of Ebola virus inhibitors however, the study of proteins solutions in different
osmolytes represents one of the active research lines of our laboratory and we
considered that such a study on VP24 could be of scientific interest.
The second part of the thesis focuses on the coarse grain method, that I learned
during my staying in the group of Prof. Siewert Jan Marrink at University of
Groningen. The case of study was the interaction of antimicrobial peptides with
negatively charged membranes.
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Chapter 1
Elements of theory
1.1 Molecular Dynamics
Molecular Dynamics (MD) [1] is a computational technique able to follow the evo-
lution of a system of interacting particles, in our case atoms, in time. In order to
perform a MD simulation we need:
 A starting structure containing the position of all atoms.
 A potential able to describe the system we are interested in.
 An integrator.
Given these three elements it is possible to follow the dynamics of the system by
the integration of Newton’s equations of motion (eq. 1.1).
d~vi
dt
=
1
mi
~fi
d~ri
dt
= ~vi
(1.1)
Where ~fi =  ~rU is the force acting on the i-th atom and mi is its mass. If we add
the initial conditions ~ri(0) = ~r0i and ~vi(0) = ~v0i this becomes a Cauchy problem
and its solution is the trajectory of the system. The starting structure is usually
provided by the Protein Data Bank, containing all the resolved X-ray structures of
proteins, nucleic acids and complex assemblies.
The aim of MD is to explore the macroscopic properties of the system (e.g. pres-
sure, energy, enthalpy) through microscopic simulations. The connection between
microscopic simulations and macroscopic properties is made by statistical mechanics
in which averages related to experiments are defined in terms of ensemble averages
1. From dynamical trajectories generated at a temperature T one can calculate the
1Ensemble average is an average taken over a large number of replicas of the system, considered
simultaneously.
4
ensemble average of any quantity A(~r), defined as
hAi 
R
d~pNd~rNe H(~p
N~rN )A(~pN~rN)R
d~pNd~rNe H(~pN~rN )
(1.2)
where H is the Hamiltonian of the classical system. Using Birkhoff’s ergodic theorem
[2] we can write the ensemble average (eq. 1.2) as a time average (eq. 1.3)
hAi = lim
n!1
1
n
nX
i=0
A(~r(ti)); (1.3)
where n is the number of snapshots that builds out the trajectory, taken at times ti.
Therefore, the aim of MD is to generate enough representative conformations such
that the ergodic hypothesis is satisfied.
1.1.1 Force Field
The basic idea behind MD simulations is the representation of the potential energy
of the system as a function of the atomic coordinates. The potential acting on the
system is calculated using a force field, and its usual expression is showed in eq. 1.4.
U(r) = Ustr + Ubend + Utors + Ucross| {z }
bonded terms
+ UvdW + Uelec| {z }
non-bonded terms
(1.4)
In this PhD thesis the AMBER force field [3] has been used, and its functional form
is showed in eq. 1.5.
U(r) =
X
bonds
kb(b  b0)2 +
X
angles
k(   0)2 +
X
dihedrals
k[cos(n+ ) + 1]
+
X
atom i
X
i>j
4ij
" 
ij
rij
!12
 
 
ij
rij
!6#
+
X
i
X
i>j
qiqj
4rij
(1.5)
The first three summation terms are over bonds, angles and dihedrals. The fourth
term describes the van der Waals interaction between non-bonded atoms, with a
Lennard-Jones (LJ) 12-6 potential and the final term represents the electrostatic
interaction between non-bonded atoms. The parameters in eq. 1.5 are optimized in
order to reproduce experimental data (X-ray diffraction, NMR and IR spectroscopy)
and quantum mechanical calculation on smaller systems.
1.1.2 Integrator
The aforementioned Cauchy problem isn’t analytically solvable in our case, because
of the nature of the U potential we are using. Under the influence of a continuous
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potential, indeed, the motions of all the atoms are coupled together, giving rise to
many-body problem that cannot be solved analytically. This is the reason why we
have to use a numerical method to solve the problem. The main idea is that the
integration can be split up in many small stages, each separated in time by a fixed
t. In this PhD thesis we employed the leapfrog integrator, which evolves position
and velocities as shown in eq. 1.6.
~ri(t+t) = ~ri(t) + ~vi(t+t=2)t
~vi(t+t=2) = ~vi(t t=2) +
~fi(~ri(t))
mi
t
(1.6)
Figure 1.1: The principle of the leapfrog algorithm.1
The advancement of positions and velocities is not synchronous. One first ad-
vances the positions, then advances the velocities based on the new positions, then
advances the positions from the new velocities, and so on.
The choice of the integration step is very important, and it depends on the algo-
rithm chosen to solve the equations of motion. Usually we are not interested in the
actual dynamics of the bonded interaction in a molecule, such as bond vibrations
which require the time step of the simulation to be smaller than 10 15s. In order to
constrain all the bonds to their equilibrium lengths LINCS algorithm [4] has been
used, allowing a time step of 2 fs.
1.1.3 Periodic Boundary Conditions
Periodic boundary conditions enable to perform a simulation of a finite system,
composed of a relatively small number of particles, avoiding border effects. To do
so, the simulation box is replicated in every direction. Coordinates of particles in
neighboring boxes can be computed adding or subtracting integral multiples of the
box sides. If a particle, during the MD simulation, leaves the box, it is replaced
by an image particle the enters form the opposite side (Figure 1.2). The most time
consuming part of a MD simulation is the calculation of the non-bonded energies,
that increases as N2. In principle, non-bonded interactions should be calculated for
every pair of atoms in the system, that are infinite if we use the pbc treatment.
1Image taken from http://isaacs.sourceforge.net/
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To overcome this problem the minimum image convention is employed. In this
convention each atom can “see” only one image of every other atom in the system.
Moreover, a cutoff is employed to truncate the interactions between pairs of atoms
whose distance is above the threshold. The cutoff has not to be so large that a
particle sees its own image in the neighboring box, it means that the maximum
limit of the cutoff value is half the length of the simulation box.
Figure 1.2: Periodic boundary conditions. 1
1.2 Coarse Grain
The Coarse grain (CG) approach consists of replacing an atomistic description of
a biological molecule with a lower-resolution coarse-grained model that averages
or smooths away fine details. These approaches have been developed in order to
investigate greater time- and length-scale dynamics that are not accessible through
atomistic simulations, such as lipid membranes and large proteins (Figure 1.3). CG
usually reduces the representation of the system, lowering the degrees of freedom.
This allows one to increase the time step of the simulation up to one order of
magnitude.
There are different choices to reduce degrees of freedom. If we think about
proteins, we can represent an aminoacid with only the heavy atoms or with one or
two united atoms per residue. For this scope several different coarse grained force
fields exist, with different levels of resolutions. In this PhD thesis we will focus on
the MARTINI force field, arguably the most widely used coarse grain model.
1Image taken from http://www.chemgapedia.de
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Figure 1.3: Application ranges for MD at different resolutions. Image taken from Ref [5].
1.2.1 MARTINI coarse grain force field for biomolecules
A large variety of CG approaches is available, and typically they are parametrized
based on comparison to atomistic simulations. MARTINI force field [6–8] has also
been developed on the basis of atomistic simulations. However the philosophy of
the force field developed by Marrink et al. is a bit different. Instead of focusing on
an accurate reproduction of structural details, MARTINI aims at a broader range
of applications. The force field is calibrated against experimental data, in particular
thermodynamic data such as oil/water partitioning coefficients. In fact, processes
as lipid self-assembly, peptide membrane binding and protein-protein recognition
depend critically on the degree of partition of the constituents between polar and
non-polar environments.
Mapping The MARTINI model is based on a four-to-one mapping, meaning that,
on average, 4 heavy atoms plus associated hydrogens are represented by a single
interaction center. Mapping of water follows the same principle, so four real water
molecules are mapped into a CG water bead. Ions are represented by one CG bead
which represents both the ion and its hydration shell. In order to represent ring-like
molecules the four-to-one mapping is too coarse, therefore this type of molecules are
mapped with an higher resolution of up to two heavy atoms per interaction center.
The force field has four main type of particle: polar, non-polar, apolar and charged.
Within each type, subtypes are distinguished based on hydrogen bonding capability
or degree of polarity. Some examples of MARTINI mapping are shown in Figure
1.4.
Non-bonded interactions Non-bonded interactions are described by a Lennard-
Jones 12-6 potential. In addition to the LJ interactions charged groups bear a charge
8
Figure 1.4: Mapping between the chemical structure at the atomistic level (AA) with
the coarse-grained Martini model for DPPC, cholesterol, water, benzene, a protein helical
fragment, and a few amino acids (valine, glutamic acid, arginine, and tryptophan). The
CG beads are shown as transparent vdW spheres. Image taken from Ref [9].
and interact via coulombic energy function. The non-bonded interactions are cut
off at a threshold distance. These interactions have been parametrized based on
experimental thermodynamic data such as free energy of hydration, vaporization
and partitioning free energies between water and a number of organic phases.
Bonded interactions Bonded interactions are described by a set of energy func-
tions analogous to the ones of a classical force field (eq. 1.5). The parametrization
was carried out with structural data obtained from atomistic simulations. The Pro-
tein Data Bank has been used as an additional source for atomistic geometries for
proteins.
Simulations parameters MARTINI simulations, due to the reduced degrees of
freedom we are considering, are stable with time steps ranging from 20 to 40 fs.
1.3 Free energy calculations: MM-PBSA approach
The Gibbs free energy (G) provides the most important information about the rela-
tionship between the structure, function and stability of biomolecules. Over the past
decade several computational approaches have been developed for the calculation of
binding free energy. While choosing an approach for free energy calculations, two
key points should be considered: accuracy and computational cost of the method.
The fastest methods for prediction of binding free energies are the empirical or
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knowledge-based approaches, which are based on simple score functions [10, 11].
The main disadvantage of the above mentioned approaches is the lack of conforma-
tional sampling which makes this methods faster at the cost of accuracy.
On the other hand, there are the most time-consuming and accurate methods, which
are based on force fields. They use MD or Monte Carlo simulations to generate
ensemble averages. Among these method free energy perturbation [12] and thermo-
dynamic integration [13] give accurate estimates but require a lot of time, thus it is
difficult to estimate binding free energies for large systems.
Since the aforementioned methods are computationally expansive, some more af-
fordable yet reliable methods have been developed. In this thesis we will use the
Molecular Mechanics-Poisson Boltzmann Surface Area (MM-PBSA) approach [14],
which combines the molecular mechanics and the PBSA model in order to compute
Gbinding of two species, using structural informations. This method is based on
the generation of different structures from an MD simulation in explicit solvent and
on the transfer of these structures in an implicit solvent.
Let’s consider the binding of a ligand (L) and of a receptor (R) forming a complex
(C). In principle we could compute the Gbinding in only one passage, using the
explicit representation of the solvent. However the major contribution to this calcu-
lated energy would arise from the interactions between the solvent molecules, with
the resulting fluctuation of the energy value (virtually greater than the Gbinding
itself). Moreover the time scale associated to this process would be too large to
be computationally simulated. In order to bypass this problem we can determine
the Gbinding exploiting the thermodynamic cycle showed in Figure 1.5, using the
implicit solvent model.
Briefly, the binding free energy of a protein to a ligand molecule in solution can
be defined as shown in eq. 1.7.
Gbinding = Gcomplex   (Gprotein +Gligand) (1.7)
MD simulation generates a thermodynamically weighted ensemble of structures. The
free energy term is calculated as an average over the considered structures, as shown
in eq. 1.8.
hGi = hEMMi+ hGsolvi   T hSMMi (1.8)
The energetic term EMM is defined as:
EMM = Eint + Ecoul + ELJ (1.9)
where Eint represents bonds, angle and torsional angle energies while Ecoul and ELJ
denote the electrostatic and Lennard-Jones energies respectively.
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Figure 1.5: The thermodynamic cycle used to calculate Gbinding of the complex in so-
lution. The binding free energy is decomposed into binding free energy in vacuum and
solvation free energy of the reacting species.1
The single trajectory method employed in this thesis to calculate binding energies
implies that the trajectories of the protein and the ligand are directly extracted from
the complex structure thus zeroing the Eint term [15].
The total binding free energy that we want to calculate is the one called Gsb in
Figure 1.5, and we can calculate it using the thermodynamic cycle:
GbS = G
g
b +G
C
SOL  GRSOL  GLSOL (1.10)
1.3.1 Solvation contribution
This contribution is divided in two components: polar and apolar, as showed in eq.
1.11.
Gsolv = Gpolar +Gapolar (1.11)
Both contributions in eq. 1.11 can be calculated using the APBS (Adaptive Poisson
Boltzmann Solver) software [16].
The thermodynamic cycle shown in Figure 1.6 incorporates several processes
into the solvation energy (step 1). Step 2 indicates charging of the solute in solu-
tion (e.g., inhomogeneous dielectric, ions present). Step 3 indicates the introduction
1Image taken from https://commons.wikimedia.org/
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Figure 1.6: The thermodynamic cycle used for the calculation of Gsolv.1
of attractive solute-solvent dispersive interaction interactions (e.g., an integral of
Weeks-Chandler-Andersen interactions over the solvent-accessible volume). Step 4
indicates the introduction of repulsive solute-solvent interaction (e.g., cavity forma-
tion). Steps 5 and 6 are basically null steps although they could be used to offset
unwanted energies added in Steps 3 and 4 above. Finally, Step 6 represents the
charging of the solute in a vacuum or homogeneous dielectric environment in the
absence of mobile ions.
Polar solvation The full free energy cycle is usually decomposed into polar and
nonpolar parts. The polar portion is represented by the charging energies in steps
2 and 6:
Gpolar = G2  G6 (1.12)
Energies returned from APBS electrostatics calculations are charging free ener-
gies. Therefore, to calculate the polar contribution to the solvation free energy, we
simply need to setup two calculations corresponding to Steps 2 and 6 in the free
energy cycle. The electrostatic charging free energies returned by APBS include
self-interaction terms. These are the energies of a charge distribution interacting
with itself. Such self-interaction energies are typically very large and extremely sen-
sitive to the problem discretization (grid spacing, location, etc.). Therefore, it is
very important that the two calculations in Steps 2 and 6 are performed with iden-
tical grid spacings, lengths, and centers, in order to ensure appropriate matching (or
“cancellation”) of self-energy terms. These polar contributions are calculated with
the Poisson-Boltzmann equation (PBE):
 r  (x)r(x) + ~2(x)sinh(x) = f(x) (1.13)
1Image taken from https://sites.google.com/a/poissonboltzmann.org/
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PBE is a non-linear partial differential equation of the second order. It relates the
electrostatic potential () to the dielectric properties of the solute and solvent (),
to the ionic force of the solution, to the accessibility of ions in solute (~2) and to the
partial charges distribution of the solute (f). In order to speed up the calculation of
this non-linear equation the Linearized PBE approximation has been used, assuming
sinh(x)  (x).
Apolar contribution Referring back to the solvation free energy cycle (Figure
1.6), the nonpolar solvation free energy is usually represented by the energy changes
in Steps 3 through 5:
Gapolar = (G3  G5) + G4 (1.14)
where Step 4 represents the energy of creating a cavity in solution and Steps 3-5
represent the energy associated with dispersive interactions between the solute and
solvent. The apolar contribution (G4) is calculated by APBS, using eq. [17]:
G4 = pV + A (1.15)
where p is the solvent pressure, V is the solute volume,  is the solvent surface
tension and A is the solute surface area.
The dispersion terms (G3 andG5) follow a Weeks-Chandler-Anderson framework
[18] (eq. 1.16):
G3  G5 = ~
Z


uatt(y)(y)dy (1.16)
where ~ is the bulk solvent density, 
 is the problem domain, uatt(y) is the
attractive dispersion interaction between the solute and the solvent at point y and
(y) describes the solvent accessibility of point y.
1.3.2 Lennard-Jones contribution
ELJ has been computed using GROMACS package [19]. Lennard-Jones short range
and 1-4 interactions have been calculated and added for every snapshot extracted
from the MD, obtaining ELJ term for complex, protein and ligand.
1.3.3 Electrostatic contribution
Ecoul represent the sum of pairwise Coulombic interactions between all atoms in
the molecule (or complex) for a particular uniform dielectric. In order to combine
these Coulombic binding energies with the solvation energies described above, we
need to make sure consistent dielectric constants are used. In particular, Coulombic
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interactions should be calculated using the same uniform dielectric constant as the
reference state of the solvation energy above. In both cases a dielectric constant of
2 has been used.
The electrostatic contribution has been computed with coulomb software equipped
in APBS package. This software, starting from “.pqr ” file containing positions,
atomic charges and radii applies Coulomb’s law (eq. 1.17) to calculate electrostatic
energy.
Ucoul =
1
40r
X
i;j
qiqj
rij
(1.17)
1.4 Protein-protein interactions
Proteins are responsible for nearly every molecular transformation of the cellular
metabolism. However, it is unlikely for a protein to act alone: approximatively 80%
of proteins in a cell don’t stand alone, but rather interact with other proteins through
protein-protein interactions in order to perform biological functions. Protein-protein
interactions (PPIs) play an important role in different cellular functions, raging from
complex formation, signalling pathways and biochemical reactions. They are defined
as the physical conctacts between two or more proteins. In order to have any biolog-
ical function these interactions have to be formed with proper partners at the right
time and locations [20]. At any time, a human cell may contain about 130k binary
interactions between proteins [21]. Any misfunction or alteration in PPIs network
can lead to various diseases, including cancer [22]. The detailed understanding of
this network of interactions can help to elucidate the molecular basis of different
diseases making PPIs a potential target for drug discovery.
1.4.1 Structural characteristics of protein protein interfaces
In principle, protein-protein binding can be driven by both polar and electrostatic
interactions. In practice, however, the binding derives from the mutual burying of
hydrophobic surfaces. At the interface aromatic residues such as Tyr, Trp, Phe and
His are more frequent than in the average protein surface (21% vs 8%). Moreover,
interfaces are richer in aliphatic residues such as Leu, Val, Met and Leu and depleted
in charged residues such as Glu, Asp and Lys. Surprisingly Arg is the residue making
the largest overall contribution to interfaces, 10% [23]. The surface of interaction is
usually very large, ranging from 1500 to 3000 Å2 for each protein.
We can classify PPIs as permanent or transient, according to their binding lifetime.
 In permanent PPIs the two proteins bind strongly, and the interface is large
and flat. In this case the packing is tighter and very few water molecules are
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trapped between monomers. The surface of interaction is mainly hydrophobic.
An example is the protein-protein complex between hemoglobin and RNA
polymerase [24].
 In transient PPIs the interactions are temporary in nature: the binding part-
ners can associate and dissociate only in particular physiological conditions.
1.4.2 Classes of atoms at protein-protein interface
The interfaces are composed of various types of atoms:
 Interface atoms are atoms that lose solvent accessible surface upon the
protein-protein binding. Not all the atoms make vdW contacts across the
interface.
 Contact atoms (Figure 1.7) are the subset of interface atoms that actually
make vdW contacts with the binding partner. They can be further classified
in fully buried and partially buried contact atoms.
– Fully buried contact atoms are accessible in the free monomers but have
zero surface accessible surface area in the complex.
– Partially buried contact atoms are partially accessible to solvent.
Figure 1.7: Side view of classes of interface atoms. All atoms of the bottom molecules
that lose solvent accessibility in the presence of the binding partner are interface atoms. In
particular type B are fully buried while type A and C retain partial solvent accessibility.
Types B and C are contact atoms, as the make vdW contacts with the top molecules.
Image taken from Ref [23].
1.4.3 Hot-spots
Not all residues at the protein-protein interface equally contribute to the binding
free energy. Only a small fraction of them, around 10%, are responsible for the
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binding of the proteins and they are called hot-spots [25,26]. Single point mutations
of one of these residues often greatly reduce affinity for the partner protein, without
changing the overall integrity of the protein [27]. Hot-spots can be experimentally
identified using Alanine Scanning. In this approach residues located at the protein-
protein interface are mutated into alanine and the difference in binding free energy
(G) is measured. Computationally we use the same kind of approach, explained
in Section 1.5.
1.4.4 PPIs in drug design
PPIs are an attractive emerging class of molecular targets as they regulate multiple
critical cellular functions such as DNA replication, transcriptional activation, trans-
lation and transmembrane signal transduction [28]. In particular, understanding
how protein-protein complexes work has allowed to elucidate the molecular basis
of different diseases. Aberrant PPIs or the loss of an essential interactions through
the formation or stabilization of protein complexes can cause diseases. However
PPIs are quite different from enzyme-inhibitor or protein ligand interactions and
designing small molecules able to target protein-protein interface is a challenging
task. First of all, protein-protein interfaces usually lack of binding pockets. The
interface is usually large, approximately 1500-3000 Å2 and it is flat. [29]. Moreover,
unlike enzymes, every PPI has to be considered as a unique case, and the binding
sites does not appear to be preserved, even among very similar interfaces [30]. It
has been shown that, for the modulation of PPIs the inhibitor, it is not required to
bind a large area of the interface: it is enough for the molecule to interact with a
small subset of hot-spots.
In principle a modulator of PPIs, to be effective, can act in two different ways:
reduce the strength of the PPI or increase the binding of the complex in order to
stabilize it. So far the vast majority of the known PPI modulators act as inhibitors
[31, 32], however in the last years also stabilizing PPI agents are gaining increasing
attention [33].
Molecules that can selectively interfere with the formation and/or stabilization
of protein-protein complexes serve as powerful research tools in chemical biology.
Three are the main classes of PPI modulators which can be identified: humanized
monoclonal antibodies, peptides and peptidomimetics and small molecules. Human-
ized monoclonal antibodies are the vast majority of PPI inhibitors in clinic, due to
their high target specificity [34]. Their principal drawbacks are the poor cell and
blood–brain barrier permeability properties and the high manufacture cost. Peptide
and peptidomimetics derived from protein-protein interface (Chapter 3) are often
the starting point for the development of small molecules PPI modulators. More-
over, they can be used as molecular probes in order to investigate the mechanism
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of PPIs modulation and for the validation of novel PPIs as targets for drug discov-
ery. However, peptides suffer from poor metabolic stability and low bioavailability.
Finally, small-molecules PPI modulators are more amenable from a medicinal chem-
istry point of view but they are very difficult to obtain.
To identify a small-molecule PPI modulator we can use three main approaches:
 Peptide and peptidomimetics approaches.
 High throughput screening of chemical libraries and natural products.
 Computational approaches based on X-ray crystallographic data.
In this thesis we discuss two of these three approaches. Peptide and peptidomimet-
ics approach consists in selecting an amino-acidic sequence at the protein-protein
interface and use it as a lead for the development of novel and improved PPI mod-
ulators (Chapter 3). Computational approaches based on X-ray crystallographic
data, such as virtual screening (Chapter 4), can lead to the identification of novel
PPIs inhibitors through the screening of a large amount of known compounds.
1.5 Computational alanine scanning
Alanine scanning (AS) mutagenesis is an experimental procedure to identify hot-
spots at the protein-protein interface [35]. It is generally a slow and labor-intensive
procedure since it requires DNA engineering, protein expression and subsequent
purification. For these reasons the alanine scanning is applied only to preselected
regions; blind AS for explorative purposes is unfeasible. However, we can use the
same technique in silico: Computational Alanine Scanning (CAS). This technique
is able to identify hot-spots evaluating the binding free energy between the subunits
making up the complex (GWT ). Afterwards the binding energy upon mutation of
each of the interfacial amino acid X into an alanine (GMut;X) is calculated. Finally,
for each residue X, a G can be obtained as:
GX = GMut;X  GWT (1.18)
Many protocols exists to perform CAS [15, 36]. They mainly differ for the sim-
ulations conditions, such as the use of one or multiple trajectories for wild type
and mutated proteins or for the use of implicit/explicit solvent. If we consider the
number of MD simulations, we can distinguish three approaches:
 Single trajectory CAS uses only the MD simulation of the wild type com-
plex. The structures are then extracted and post-processed in order to obtain
the mutated complexes. Monomers are obtained from the same simulation
discarding the partner protein from the complex structure.
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 Double trajectory CAS uses two simulations: one for the wild type and
one for the mutated complex. Monomers are obtained as in the former case.
 Quadruple trajectory CAS uses four MD simulations: wild type and mu-
tated complex and the two monomers.
In recent studies it has been demonstrated that single trajectory CAS gener-
ally has better results due to a convenient error cancellation. In multiple trajectory
the error due to insufficient sampling strongly affect the results. Moreover using
a single trajectory allows to neglect the entropic terms of the G because the
identity of the structures leads to the mutual cancellation of this term. Regarding
the solvation there isn’t an agreement about which approach would achieve better
results. While, in general, a better description of the solvent is preferred, supporters
of implicit solvent claim that, since the calculation of the solvation term in MM-
PBSA method is done with implicit solvent, it is better to perform MD in the same
conditions. In this work the single trajectory CAS in explicit solvent is carried out,
using MM-PBSA method for the calculation of the binding free energy.
Mutating all interfacial amino acids and calculate the GX in the aforemen-
tioned way yields a map predicting which residues are important for the ligand (or
protein) binding and which are not. This amino acids tend to be grouped into
small clusters on the interface and they are classified on the basis of difference
in binding free energy between the wild type and the mutant type as “hot spots”
(G > 4 kcal mol 1), “warm spots” (2 kcal mol 1 < G < 4 kcal mol 1)
and “cold ” or “null spots” (G < 2 kcal mol 1) [37]. Figure 1.8 represents the
procedure for the CAS computation.
Some assumptions have been made in the calculation of G with the CAS
approach, which are follows:
 Point mutations in the protein do not significantly affect the conformation of
the mutated protein. The validity of this assumption in computational alanine
scanning has been widely confirmed in literature when it has been applied both
to protein–protein and to protein–small molecule complexes [15, 38,39].
 The terms in the energy function used for the calculation of G (Section 1.3)
are pairwise additive. This assumption is necessary for the fast computational
evaluation of the binding free energy.
 Cofactors, metal ions and water molecules participating in hydrogen bonding
at the protein interface are not taken into account
 Proline residues are not mutated into an alanine and thus not considered for
CAS. This is because its backbone conformation is different from the one of
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Figure 1.8: Flowchart illustrating the procedure of the computational alanine scanning
approach.
alanine, and the mutation would lead to significant conformational changes
[40].
1.6 Root mean-square fluctuation
The Root Mean Square Fluctuation (RMSF) (eq. 1.19) is the measure of the devi-
ation between the position of an atom i during the dynamic and its time-averaged
position.
RMSF =
vuut 1
T
TX
tj=1
(xi(tj)  xi)2 (1.19)
where T is the time over which one wants to average and xi is the time-averaged
position of the atom i.
1.7 Essential dynamics
Essential Dynamics (ED) [41] is a very powerful analysis technique which exploits a
Principal Component Analysis (PCA) [42] to identify the nature and relative impor-
tance of the essential motions of a macromolecule from a MD sampling. The result
of an ED analysis is a set of eigenvectors, which describe the nature of motions in
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the Cartesian space, and eigenvalues, which represent the amount of variance de-
scribed by each eigenvector. The ED method is able to separate the few large mainly
unharmonic motions (the essential subspace) from the small Gaussian fluctuations
(the near-constraints subspace) [43]. The motions in the essential space are linked
to the biological functions of the protein.
Given a MD trajectory, the overall translational and rotational motions have to be
eliminated. The result is a Cartesian molecular coordinate system in which atomic
motions can be expressed. The internal motion is now described by a trajectory
~x(t), where ~x is the 3N-dimensional vector of all atomic coordinates, represented by
a column. The correlation between atomic motions can be expressed in the covari-
ance matrix C of the positional deviations, whose element Cij expression is shown
in eq. 1.20:
Cij = hM
1
2
ii (xi(t)  hxii)M
1
2
jj(xj(t)  hxji)i (1.20)
where the brackets denote an average over time. The symmetric 3Nx3N covari-
ance matrix can be diagonalized by an orthogonal coordinate transformation R:
RTCR = diag(1; 2; :::; 3N) (1.21)
The columns of R are the eigenvectors or principal mode. The eigenvalues 
represent the variance in the direction of the corresponding eigenvector. The original
MD can now be projected on the eigenvectors, in order to obtain the principal
components pi, i=1,...,N [44].
~p(t) = RTM
1
2 (~x(t)  h~xi) (1.22)
Carrying out the visual inspection of the trajectory projected on the eigenvectors
we can highlight the most important collective motions of the protein during the
dynamics.
1.8 Molecular Docking
Docking is a computational method able to predict the structure (or structures) of
the intermolecular complexes formed by a ligand and a receptor (usually a protein).
Docking can be employed to investigate the binding modes of protein inhibitors.
The docking algorithm consists of two distinct phases: posing and scoring. In the
posing phase the program generates a large number of possible structures. Once
the structures have been generated, we require a mean to score each structure and
identify the most lowest energy ones [1].
The are two ways to perform a molecular docking calculation: flexible and rigid.
The flexible docking involves many degrees of freedom: there are six translational
20
and rotational degrees of freedom of one molecule relative to the other as well as the
conformational degrees of freedom of each molecule. The rigid docking considers
the ligand and the receptor as rigid objects that cannot change their conformation
during the docking process. Various docking algorithms have been developed in
the last few decades, and they are more complex the more degrees of freedom they
consider. In this PhD thesis the DOCK6 [45] algorithm was employed.
Figure 1.9: Schematic illustration of molecular docking.1
1.8.1 DOCK6 algorithm
Posing DOCK is designed to find molecules with high degree shape complemen-
tarity to the binding site. First of all the program builds a negative image of the
protein binding site, that consists of a collection of overlapping spheres with varying
radii. This negative image is built by rolling a ball with the size of a water molecule
over the van der Waals surface of the target. Each sphere touches the molecular
surface at just two points and has its radius along the surface normal (Figure 1.10).
Spheres are calculated over the entire surface and subsequently this very dense rep-
resentation is filtered to keep only the largest sphere associated with each receptor
surface atom. Ligand atoms are then associated to the sphere centers in order to
find matching sets in which all the distances between the ligand atoms in the set are
equal to the corresponding sphere center-sphere center distances (within a certain
tolerance).
To include the internal degrees of freedom of the ligand, DOCK uses the anchor-
and-grow incremental construction approach [47]. This kind of approach separates
the ligand flexibility in two steps. The largest rigid structure of the ligand (anchor)
is identified and rigidly oriented in the active site by matching its heavy atoms
centers to the receptor sphere centers. The anchor orientations are optimized using
the scoring function. Then, the remaining flexible portions of the ligand are build
onto the best anchor orientation within the context of the receptor.
1Image taken from https://commons.wikimedia.org/
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Figure 1.10: Schematic representation of a binding site (thick line) formed from five atoms
(thin circles). Image taken from Ref [46].
Scoring DOCK scoring function is based on the AMBER [3] force field. Only the
interactions between the ligand and protein are considered, leaving only intermolec-
ular van der Waals and electrostatic components in the function. Since the receptor
is considered to be rigid, the receptor contribution to the potential energy can be
pre-calculated and stored on a grid. These approximations enable the program to
evaluate large libraries of small molecules against a receptor in a reasonable period
of time.
1.8.2 Virtual Screening
Virtual screening is a computational technique that consists in the search of libraries
of chemical compounds that could be able to bind a drug target, usually proteins
or enzymes. There are plenty of free database of commercially available compounds
that can be used as a starting point for a virtual screening. Typically there are two
major categories of screening technique: ligand based and structure based.
Ligand based If we already know the structure of some ligands that bind to the
receptor, their pharmacophore can be obtained. Then, using the pharmacophore
model, one can scan the database of compounds in order to find molecules that are
compatible with the model.
Structure based Structure based virtual screening involves the docking of a
database of compounds in the binding site of the receptor. Every docking pose
is evaluated with a scoring function to asses the ability of the ligand to bind in that
particular site.
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1.9 Preferential Coefficient and Solvent Density Func-
tion
The presence of cosolvents usually alters the chemical potential of the protein. They
can associate more strongly or more weakly with the protein with respect to wa-
ter. This phenomenon is called preferential binding and it is of a great importance
because it has an effect on the physical and chemical properties of proteins. In eq.
1.23 is shown how a consolvent alters the chemical potential of a protein.
trP =
Z mx
0
 
@P
@mX
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mP
dmX
=  
Z mx
0
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where trP is the transfer free energy of the protein (P) from pure water into the
water and cosolvent (X) system and m is the molality. The first partial derivative
in eq. 1.23 represents the dependence of the protein’s chemical potential on the
cosolvent molality. The second is the preferential coefficient  XP .
 XP 
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The preferential coefficient  XP measures the ratio of cosolvent molecules in the
neighbourhood of the protein with respect to the bulk. According to Baynes and
Trout [48],  XP can be evaluated defining two domains (Figure 1.11) as shown in
eq. 1.25.
  =
*
nIIX   nIIW

nIX
nIW
+
(1.25)
Where nI;IIX;W is the number of water (W) or osmolyte (X) molecules in the bulk
domain (I) and local domain (II).  XP is independent of the choice of the boundary
between the domains if the boundary is far enough from the protein.
The preferential coefficient is greater than zero if the amount of cosolvent in the
neighbourhood of the protein is higher than in the bulk. This behavior is verified
for denaturants such as urea. The opposite behavior happens with osmoprotectants.
Solvent Density Function (SDF) describes how the cosolvent is distributed
around the protein. The idea behind this function is the same of radial distri-
bution function. The main difference is that, in the case of the SDF, the shape
and the volume of the protein are taken into account. The function for a generic
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Figure 1.11: The two different domains defined in order to calculate the preferential coef-
ficient. Image taken from Ref [48].
molecule X is computed as shown in eq. 1.26.
X(r) =
X(r; r0)
V (r; r0)
(1.26)
Where r represent the radius of the solvation shell, X(r; r0) is the number of
cosolvent molecules found from r to r’, and V (r; r0) is the volume of the shell r, r’.
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Part I
Molecular modeling of Ebola virus
inhibitors
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Ebola virus
Ebola Virus (EBOV) belongs to the Filoviridae family of single stranded, non-
segmented negative-sense RNA viruses. The shape of the virus is variable, usually
appears as long tubes with many turns and branches (Figure 1.12).
Figure 1.12: Morphology of Ebola virus. 1
Ebola virus genome codes for seven proteins. The seven genes are for the nucle-
oprotein, the viral proteins VP24-VP30-VP35-VP40, L (polymerase) and the gly-
coprotein (Figure 1.13). The surface glycoprotein is expressed in two molecular
forms, GP1 and GP2 that are generated by editing the RNA. It has a fundamental
role in the pathogenesis of the virus and in the infection, its replication is tightly
regulated during virus replication. The nucleoprotein embeds the genetic material
and interacts with VP35 and VP30 forming a large protein-protein complex that
is involved in the synthesis of virus RNAs. VP40 and VP24 are localized in virus
matrix space [49–52].
Only one of these seven protein, the viral large (L) RNA-dependent RNA poly-
merase protein, has an enzymatic activity, while all the remaining EBOV proteins
exert their function through protein–protein interactions, among themselves or with
human proteins.
Five species of Ebola virus are known and they are named after the region where
they have been identified for the first time: Bundibugyo, Reston, Sudan, Taï Forest
and Zaire.
1Image taken from https://www.cdc.gov/
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Zaire Ebola virus is the causative agent of haemorrhagic fever with a very high hu-
man fatality rate near 90% [53]. Recently EBOV has spread in several countries in
Africa and a few sporadic cases were registered also in Europe and in the US. The
lack of effective therapies or vaccines, combined with this high mortality rate, makes
urgent the need to develop antiviral drugs against EBOV.
The virulence and high lethality of this virus are due to different factors, in partic-
ular to its ability to inhibit both the innate immune response in the early stages of
infection and the subsequent adaptive specific immune responses of the host organ-
ism [54, 55]. This is done by different strategies, in particular by the suppression
of interferon (IFN)-= production and inhibition of interferon induced antiviral
activity [56,57].
In this part we will focus our attention on Viral Protein 35 (VP35) and Viral Protein
24 (VP24).
Figure 1.13: Schematic representation of Ebola Virus virion.1
1Image taken from: http://virologydownunder.blogspot.it/
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Chapter 2
In silico study of VP35 inhibitors
2.1 Viral Protein 35
Viral Protein 35 (VP35) is one of the seven proteins coded by Ebola genome and it
carries out multiple functions, including the inhibition of RNA dependent protein
kinase (PKR) [58,59], suppression of RNA silencing [60] and the inhibition of inter-
feron (IFN)-= signaling [61]. The activation of IFN-= productions is one of the
key steps in the innate immune response to viral infection. In this activation the
trascription factor interferon regulatory factor 3 (IRF-3) plays a fundamental role.
IRF-3 is a cytoplasmatic protein that becomes hyperphosphorylated on serine and
threonine residues, dimerizes, and accumulates in the nucleus, where it participates
in initial IFN-= gene expression [62–64]. It has been found that VP35 interfers
with the activation of IRF-3, thus it is responsible for the inhibition of IFN-=
production [65]. This makes VP35 a potential therapeutic target.
VP35 consists of a N-terminal coiled-coil domain, required for its oligomerization,
and a C-terminal domain, called the interferon inhibitory domain (IID), required
for the interaction with the viral Nucleoprotein (NP) and for interferon inhibition.
Two basic patches are found in the IID:
 The first basic patch (FBP), important for interactions with EBOV NP and
VP35 polymerase cofactor function.
 The central basic patch (CBP), important for VP35 dsRNA binding and IFN
inhibition.
The high resolution structure of the C-terminal domain has been recently ob-
tained. It is made up by two different subdomains (Figure 2.1): a N-terminal
-helical subdomain and a C-terminal -sheet subdomain [66,67].
In a recent study Brown et al. [66] determined the crystallographic structures
of VP35 in a complex with nine small molecules able to inhibit the protein–protein
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Figure 2.1: VP35 in complex with one of the ligands (GA017). The -helical subdo-
main (residues from Ala221 to Arg283) is represented in green and the -sheet subdomain
(residues from Val294 to Ile340) is represented in blue. The binding mode is the same for
all ligands.
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interaction between VP35 and NP. In this chapter we study at the atomic level the
interactions between these inhibitors and VP35 by performing molecular dynam-
ics simulations and computational alanine scanning on these systems, in order to
identify the key interactions for the binding of ligands, thus providing hints for the
further optimization of active molecules targeting VP35. Then, to better character-
ize and distinguish the dynamic behavior of the apo-protein from the ligand–protein
complexes we measure residues RMSF and perform an essential dynamics analysis.
We finally compare the dynamic behavior of the apo-forms of EBOV and Marburg
virus VP35.
2.2 Computational details
Molecular dynamics The ligand-protein complexes and the apo-protein struc-
tures of EBOV and Marburg Virus (MARV) VP35 were obtained from the Pro-
tein Data Bank (PDB codes: 4IBB, 4IBC, 4IBD, 4IBE, 4IBF, 4IBG, 4IBI, 4IBJ,
4IBK [66],3FKE [67],4GH9 [60]). Molecular dynamics simulations were performed
with the GROMACS 4.5.3 [19] package using explicit solvent and periodic boundary
conditions.
The AMBER99SB-ILDN [68] force field was used for the protein and the Generalized
Amber Force Field [69] for ligands. Each complex was solvated with TIP3P [70] wa-
ters and neutralized with two chloride ions. The LINCS algorithm [4] was employed
to constrain all bonds involving hydrogen to their equilibrium length, allowing a time
step of 2 fs. The systems were submitted to 10000 steps of geometry optimization
with the steepest descent method. Then they were equilibrated for 200 ps in NVT
conditions (T = 300 K) and subsequently for 200 ps in NPT conditions, in order
to equilibrate systems density. Then a 25 ns molecular dynamics was performed
for every system in NPT conditions (1 bar, 300 K). Temperature and pressure were
kept constant to their reference values using the velocity rescale algorithm [71] and
the Berendsen barostat respectively [72]. A 14 Å cutoff was applied for non-bonded
interactions and the Particles Mesh Ewald algorithm [73] was employed to calculate
long range electrostatic interactions.
CAS To perform computational alanine scanning, 250 snapshots were extracted
from the last 5 ns of each dynamics (one snapshot every 20 ps). Residues at the
ligand–protein interface were selected using Naccess [74]. For each residue at the
interface all side chain atoms beyond C were removed and the missing hydrogen
was added, obtaining an alanine side chain. G of binding was calculated using the
MM-PBSA approach (Section 1.3). The Poisson–Boltzmann equation was solved
with APBS [16] using a relative dielectric constant of 80 for the region around the
30
protein and of 2 for the protein interior. The entropic contribution toG is supposed
constant in the mutated and wild type structure considering their similarity, so it
has not been calculated, as discussed by Kollman et al. [36].
Bootstrap root mean-square fluctuations analysis For this analysis we ap-
plied the protocol described in the work by Mitra et al. [75]. We first determined
the number of independent conformations in our MD trajectories by calculating the
autocorrelation function of Root Mean Square Deviation (RMSD) of the structures.
We found a correlation time of 2:5 ns, corresponding to 10 independent structures
in each of our 25 ns trajectories. In order to calculate the RMSF we selected 10
random points with replacement, from every dynamics and repeated it 200 times,
giving us a mean RMSF value and a standard error of the mean for each residue in
the protein. Using these values we applied a student’s t-test to the data and iden-
tified contiguous regions that showed significant differences at a significance level of
p < 0:0005.
Essential dynamics The covariance matrix and its diagonalization were calcu-
lated with the g_covar utility of GROMACS 4.5.3, the analysis of the eigenvalues
and eigenvectors with g_anaeig. The visual inspection of the projection on the first
3 eigenvectors was carried out using the VMD software [76].
2.3 CAS
Computational Alanine Scanning on the residues at the protein–ligand interface was
carried out in the last 5 ns of the molecular dynamics trajectories, when the system
was fully equilibrated in all cases, as shown by RMSD plots (Figure 2.2 and Figure
2.3).
In general, once equilibrium has been reached, trajectories 5 ns long guarantee
enough sampling for an accurate binding free energy calculation with the MM-PBSA
approach and consequently for computational alanine scanning purposes [77,78]. All
the complexes exhibit a negative protein–ligand Gbinding during the simulations
(Table 2.1).
The interface is defined as the ensemble of amino acids whose solvent exposed
surface area has a non-zero variation upon complex formation. Ligand molecules
(shown in Figure 2.4) share the same binding site and 18 residues in total were found
to be at the interface for each molecule. CAS results are summarized in Table 2.2.
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GA017 GA246
VPL27 VPL29
VPL42
Figure 2.2: RMSD values fitting protein C for every protein ligand complex (1/2).
Name Gb=kcal mol 1 =kcal mol 1
GA246 -47:32 5:69
GA017 -41:46 2:36
VPL60 -40:72 5:28
VPL27 -40:42 4:48
VPL48 -40:40 4:98
VPL58 -39:23 4:27
VPL42 -39:15 5:05
VPL57 -38:15 5:28
VPL29 -37:00 4:72
Table 2.1: Protein-ligands Gbinding energies.
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VPL48 VPL57
VPL58 VPL60
Figure 2.3: RMSD values fitting protein C for every protein ligand complex (2/2).
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GA017 GA246 VPL27
VPL29 VPL42 VPL48
VPL57 VPL58 VPL60
Figure 2.4: Molecular structures of simulated ligands.
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Residue numbering and domain names are taken from Leung et al. [67]. In
Figure 2.1 the two subdomains of VP35 are shown. The -helical subdomain con-
sists of residues Ala221–Arg283 and the -sheet subdomain is formed by residues
Val294–Ile340. The loop Val284–Pro293 connects the two subdomains. The binding
site is the same for all the ligands and it is located between the -helical and the
-sheet subdomains.
Six amino acids are found to be hot-spots in all the simulated complexes, namely
Lys222, Arg225, Gln244, Lys248, Lys251 and Ile295 (Figure 2.5).
Figure 2.5: An overview of the hot-spot residues in the GA017–VP35 complex. These
residues are common to all the complexes studied.
Brown et al. [66] performed experimental mutation of Lys248 or Ile295 into
alanine, showing that these two residues are of paramount importance for ligands
binding, as their mutation resulted in a near complete loss of binding affinity for
all the tested ligands. Our computational results mirror the available experimen-
tal ones, furthermore they led to the identification of four new hot-spots residues
exerting a critical function in the protein–ligand interaction. All the molecules con-
sidered in the present study share an almost equal orientation within the binding
pocket, with the common carboxylic group oriented toward a region of the protein
containing a cluster of positive charged residues, such as Lys222, Lys251, Lys248
and Arg225, which are all hot-spots, the most prominent two being Lys248 and
Lys251. Lys251 forms a strong salt bridge with the carboxylic group of the ligands,
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which is observed in all the simulations. The loss of this interaction upon mutation
into alanine explains the high value of G of the residue in all the complexes. In
some cases, such as the GA017, GA246 and VPL29 complexes, the average distance
between the carboxylic carbon and the charged lysine nitrogen is below 4 Å, the
interaction being almost continuously present during the MD run. In other cases,
for example the VPL27 complex, the average distance is around 5 Å, resulting in
a lower G. Lys248, although bearing a positive charge, also forms hydrophobic
interactions through its aliphatic chain with the B and D rings of the ligands (Figure
2.2). A coulombic interaction between opposite charges of Lys248 and the carboxylic
group of the ligands is likely to be also present. Analysing the geometries of the
complexes during the simulations and measuring the average distance between the
carboxylic carbon and the charged lysine nitrogen, it is clear that the contribution
of the hydrophobic interaction is constant for all the complexes, while the different
values of Lys248 G are modulated by electrostatic interactions during the dy-
namics. For VPL29 and VPL57, showing the higher G value, the mean distance
is around 5.5 Å, instead for VPL48 and GA246 this value is over 7 Å. Lys222 and
Arg225 do not form stable salt bridges during the dynamics, but they are affected
by the proximity of the ligand’s carboxylic group. Their G values are lower than
those of the aforementioned positive charged residues. Ile295 interacts with the
D and C aromatic rings of the ligands; these interactions are mainly hydrophobic.
Interestingly, Asp252 exhibits a negative G in all the complexes. This is proba-
bly due to its proximity to the negatively charged carboxylic group of the ligands.
Substituting this residue with an alanine results in the loss of this disadvantaged
interaction. Asp302 exhibits the same behavior, albeit to a lower extent (see Table
2.2).
2.4 Root mean-square fluctuations bootstrap anal-
ysis
To further characterize the dynamic behavior of EBOV VP35 and how it is affected
by ligand binding, C root mean-square fluctuations were calculated for the apo-
form and for each protein–ligand complex. As we can notice in Figure 2.6, there
are five protein segments exhibiting a fluctuation larger than average, correspond-
ing to residues His231–Phe235, Ile246–Ser253, Ser266–Ser272, Pro293–Ile297 and
Phe328–Leu336.
Segments comprising residues His231–Phe235 and Ser266–Ser272 correspond to
loop regions connecting -helices, which have an intrinsically larger mobility than
neighboring residues, so we focused our analysis on the Ile246–Ser253, Pro293–Ile297
and Phe328–Leu336 segments (Figure 2.7), which all show significant differences in
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Figure 2.6: RMSF bootstrap analysis. Three protein segments have been further analyzed,
due to their larger flexibility: Ile246–Ser253, Pro293–Ile297 and Phe328–Leu336 (see text).
RMSF between the apo-protein and the complexes, according to student’s t-test.
Figure 2.6 shows that residues ranging from Pro293 to Ile297, belonging to the
-sheet subdomain, exhibit a higher RMSF value in the apo-form than in all the
complexes. A similar behavior is also evident in residues ranging from Ile246 to
Ser253 belonging to the -helical subdomain. The presence of any ligand reduces
the fluctuation of these two regions which compose the binding site, and they are
thus less flexible upon ligand binding. Moreover, RMSF exhibits a sharp peak
corresponding to the region between residues Phe328 and Leu336. Here RMSF
reaches values around 0:2 nm for the apo-form and even greater for the VPL60,
VPL57 and VPL58 complexes. These ligands seem to exalt the flexibility of these
residues. Finally, root mean square fluctuation analysis was performed on MARV
VP35. On the whole, more flexible loops correspond to those observed in the EBOV
protein (Figure 2.8), as expected due to the high homology and great structural
similarity between the two proteins.
2.5 Essential dynamics
In order to better understand the results arising from RMSF analysis we performed
essential dynamics (ED) calculations on the apo-protein and on all the simulated
38
Figure 2.7: Flexible domains of VP35.
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Figure 2.8: Comparison between RMSF values of EBOV and MARV VP35.
complexes. The MD trajectories were processed by principal components analysis
considering the protein C for the construction of the covariance matrix. For each
system, the projection of the trajectory on the three eigenvectors corresponding to
the greater eigenvalues were visualized. In all the systems the first three eigenvectors
represent at least 30% of the global motion.
The ED analysis of the apo-form of VP35 highlights two kinds of motions. The
projection along the first two eigenvectors describes a closing motion of the -
sheet subdomain on the -helical subdomain. In particular loops Pro293–Ile297 and
Phe328–Leu336, both belonging to the -sheet subdomain, appear to bend towards
the residues Ile246–Ser253 of the -helical subdomain (Figure 2.9). The projection
on the 3rd eigenvector shows the motion of the Phe328–Leu336 loop alone. These
results strictly mirror the observations from the RMSF analysis, where the afore-
mentioned groups exhibited the higher mobility. For the apo-form the first three
eigenvectors describe more than 50% of the collective motion of the protein.
The presence of some ligands, such as GA017, GA246 and VPL29, hinders the
closing motion observed in the apo-form; the projection on the first eigenvector of
the GA017 complex is the same as the apo-form, but the amplitude of the motion is
smaller. Also in this case we confirm our previous observation from the RMSF anal-
ysis, as RMSF values for residues Ile246–Ser253 and Pro293–Ile297 of the complexes
were lower than for the apo-protein.
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A B
Figure 2.9: A panel: schematic representation of the projection of the MD simulation
on the 1st eigenvector extracted from the ED of the apo-protein. Highlighted in or-
ange and green we can see the closing motion of the -sheet subdomain towards residues
Ile246–Ser253 belonging to the -helical subdomain, highlighted in yellow.
B panel: The projection of the MD simulation on the 1st eigenvector of the VPL57–VP35
complex. Highlighted in green we can see the intense motion of the Phe328–Leu336 loop.
The characterizing closing motion of the apo-protein is not present in this case.
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Interestingly, the RMSF analysis suggested that ligands VPL57, VPL58 and
VPL60 could exalt the motion of residues between Phe328 and Leu336. The pro-
jections on the first three eigenvectors for the VPL60 complex trajectory show an
intense movement of these residues. In this case the characteristic closing motion
observed in the apo-form was not detected, while it was significantly reduced in
VPL57 and VPL58 complexes. For the VPL60 complex the first three eigenvectors
describe about 48% of the global motion. For the VPL57 complex the projections
on the 1st and 2nd eigenvector show a very large motion of the loop Phe328–Leu336
(Figure 2.9) while the projection on the 3rd eigenvector describes the closing motion
of the -sheet subdomain towards the -helical subdomain.
Finally, VPL58 has a similar behavior, the projection of the trajectory on the 1st
eigenvector resulting in a large motion of the Phe328–Leu336 loop and the projec-
tions on the 2nd and 3rd eigenvectors representing the closing motion of the -helical
subdomain on the -sheet subdomain. The first three eigenvectors of both VPL57
and VPL58 describe almost 40% of the collective motion of the complex.
2.6 Conclusions
We studied EBOV VP35 and its inhibitors from a computational point of view.
We performed both MD simulations of apo-protein and complexes starting from
the crystallographic structures and CAS, obtaining a very good agreement with the
structural and biochemical experimental results. We deepened the study of this
systems from the point of view of the intermolecular interactions, identifying new
hot-spots in addition to those experimentally determined. Then we performed the
RMSF bootstrap analysis, in order to identify the most mobile residues and to
highlight the difference between the apo-protein and the complexes. In particular
we identified three protein segments whose behavior was different in the apo-protein
compared to the complexes.
To characterize the RMSF results, in order to analyze the global motion of the
systems, we performed ED analysis, obtaining the collective and most important
motion for every system. We noticed that ligands hinder the typical closing motion
of the  sheet-subdomain towards the  helical-subdomain of the apo-form. The
binding of some ligands, like VPL57 VPL58 and VPL60, exalts the movement of
the loop Phe328–Leu336.
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Chapter 3
Computer aided design of an
oligopeptide targeting VP24
3.1 Introduction
Viral Protein 24 (VP24), acts as an inhibitor of interferon (IFN) signaling. Immune
response of the organism to a viral infection is due to interferons, through the phos-
phorylation of the STAT (signal transducer and activator of transcription) protein
operated by the Janus kinase [79]. The phosphorylated STAT is recognized by a
subset of Karyopherin  (KPNA) family of nuclear transport factor. This STAT-
KPNA complex is transported in the cell nucleus where it induces the expression of
ISG gene, that has an antiviral activity [80,81]. VP24 acts in a cell intrinsic manner
inhibiting IFN signaling and making cells refractory to IFN as it forms a complex
with KPNA, thus making it unavailable for the STAT transportation into the cell
nucleus (Figure 3.1) [82].
Inhibition of VP24-Karyopherin interaction is a possible therapeutic strategy to
reduce Ebola virulence. Targeting Protein-protein interactions (PPIs) is a difficult
task, due to the inherent features of protein-protein contact surfaces, which are
often flat and lack well defined pockets, and to their variability (Section 1.4) [30,
83]. Nevertheless, in recent years many encouraging results have been obtained,
showing that exploiting PPIs as therapeutic targets is a viable, albeit challenging
option [84,85] and several PPIs targeting molecules, both of peptidic [28,86,87] and
non peptidic nature [88–90], have been described. Among the molecular modeling
techniques aimed to study PPIs, computational alanine scanning [36] (Section 1.5)
is a widely used one. This kind of approach has been successfully used to identify
peptides acting as PPIs inhibitors and corresponding to protein subsets located at
the protein-protein interface [91], as well as to describe the interactions between
protein surface and small molecule binders [92].
VP24 adopts a compact, single domain, = structure of novel fold. The overall
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Figure 3.1: Left panel: In a healthy organism the C-terminal domain of KPNA binds to
the STAT forming a protein-protein complex able to reach the cell nulceus.
Right panel: VP24 binds to the C-terminal domain of KPNA, making it unavaiable to
transport the STAT in the cell nucleus. Image taken from Ref [82].
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shape of VP24 resembles a triangular pyramid, the three faces of the pyramid are
numbered 1, 2 and 3 (Figure 3.2). A collection of  helices (1 and 5-10) and a
small, three-stranded, antiparallel  sheet (1-3) form the top of the pyramid with
the N-terminus at the apex. A five-stranded antiparallel  sheet (4-8) forms the
center, while a second collection of  helices (2-4) forms the base [93].
Figure 3.2: VP24 pyramidal structure. Image taken from Ref [93].
In this work we performed an atomic level mapping of the interactions between
VP24 and KPNA, employing molecular dynamics simulations in explicit solvent
and free energy calculations, and identified a small subset of residues at the VP24-
KPNA interface responsible for protein complex formation. In particular, such criti-
cal residues belonging to Karyopherin were used as the basis for the design of a nine
residues long peptide potentially able to interact with VP24, thus competitively in-
hibiting its interaction with Karyopherin. To evaluate whether the identified peptide
could retain its ability to interact with VP24 even when extracted from its protein
environment, molecular dynamics simulation of the peptide-VP24 complex was per-
formed, as well as CAS, in order to evaluate the structural and energetic behavior
of the peptide. The interaction between VP24 and the identified peptide was then
experimentally investigated through advanced NMR techniques. The interactions
between the Ebola receptor and the nonapeptide ligand are governed by weak forces
including Van der Waals interactions, hydrogen bonding and hydrophobic associa-
tions. In this case, the ligand-based NMR approach represent an optimal angle of
observation, because it permits the analysis of interactions governed by weak equi-
librium dissociation constants (in the micromolar to the millimolar range), focusing
on the ligand. We confirmed the binding of the peptide with VP24 protein and
mapped the interaction epitope by determining the ligand regions in contact with
the receptor.
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3.2 Computational details
Molecular Dynamics The crystallographic structure of the complex VP24-KPNA
was obtained from the Protein Data Bank (PDB code: 4U2X [82]), and the residue
numbering used here is referred to such structure. Molecular dynamics simulations
were carried out with the GROMACS 4.5.3 [19] package using explicit solvent and
periodic boundary conditions. The AMBER99SB-ildn [68] force field was used. Ev-
ery system was solvated with TIP4P [94] waters and neutralized with Cl  or Na+
ions to reach neutrality. The LINCS algorithm [4] was employed to constraint all
bonds to their equilibrium length, allowing a time step of 2 fs. The system was sub-
mitted to 10000 steps of geometry optimization with the steepest descent method.
Afterwards it was equilibrated for 200 ps in NVT conditions (T=300 K) and subse-
quently for 200 ps in NPT conditions, in order to equilibrate system density. For the
VP24-KPNA complex a 50 ns molecular dynamics was performed in NPT conditions
(1 bar, T=300 K). For each of the peptide-VP24 complexes, a 100 ns MD simula-
tion was run in the aforementioned conditions. Temperature and pressure were kept
constant at their reference value using the velocity rescale algorithm [71] and the
Berendsen barostat [72], respectively. A 14 Å cutoff was applied for non-bonded
interactions and the Particles Mesh Ewald algorithm [73] was employed to calculate
long range electrostatic interactions.
Computational alanine scanning 500 snapshots were extracted from the last 20
ns of the dynamics of the VP24-KPNA complex (one snapshot every 40 ps). Solvent
accessible surface area (SASA) of each residue was calculated using Naccess [74].
The G of binding was calculated with the MM-PBSA approach as implemented
in the GMXPBSA 2.0 suite [95, 96]. This protocol implicitly assumes that point
mutations in the protein do not significantly affect its conformation. The validity
of this assumption in computational alanine scanning has been widely confirmed
in the literature, when applied to protein-protein interactions [97, 98]. A dielectric
constant of 2 was chosen for protein interior. The same protocol was employed for
the computational alanine scanning for each of the VP24-peptide complexes.
3.3 Computational Alanine Scanning results
A molecular dynamics of 50 ns was performed on the VP24-KPNA complex. Com-
putational Alanine Scanning (CAS) was carried out in the last 20 ns of the dynamics
when the system was fully equilibrated as shown by RMSD plot (Figure 3.3).
In general, a few nanoseconds long trajectories allow a sufficient sampling for an
accurate binding free energy calculation with the MM-PBSA approach and conse-
quently for CAS purposes [77, 78]. The protein-protein interface is defined as the
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Figure 3.3: RMSD versus time for VP24-K complex C atoms considering the crystal
structure as reference.
ensemble of amino acids whose solvent exposed surface area has a nonzero varia-
tion upon complex formation and it is composed of 56 residues. Residues whose
mutation led to a variation in binding free energy (G) greater than 2 kcalmol 1
are defined as hot-spots. CAS results are summarized in Table 3.1. Hot-spots are
evenly distributed between VP24 and KPNA, which contain 10 and 11 hot-spots
respectively (Figure 3.4).
The two proteins exhibit a high degree of electrostatic complementarity, as can
be inferred from electrostatic potential maps (Figure 3.5). A more detailed insight
into the network of interactions at the interface that contribute to VP24-KPNA
complex formation can be achieved by the analysis of the local environment of the
hot-spots during the simulation.
As we can see from Table 3.4, since most of the hot-spots are either charged
or polar residues, most of the interactions within the VP24-KPNA complex are
salt bridges and hydrogen bonds, although hydrophobic hot-spots and non-polar
interactions are also observed. In particular, Arg140 and Glu475’ (residues belonging
to KPNA are labeled with a prime on their sequence number) form a salt bridge that
is populated along 88% of the MD trajectory, while salt bridges between Glu203
and Lys399’, between Asp205 and Arg396’ and between Asp124 and Lys481’ are
populated during 85%, 78% and 64% of the trajectory respectively (Figure 3.6).
Residue Asp124 is also involved in a hydrogen bond between its carboxyl group
and Thr434’ hydroxyl, which is observed during 75% of the simulation, while Arg137
and Asp480’ backbones form a hydrogen bond for 74% of the trajectory. A small
hydrophobic cluster, comprising Leu121, Val141 and Tyr477’, Phe484’ and the
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Mutation G=kcal mol 1 err=kcal mol 1
GLU88 -10.99 0.79
GLU113 6.16 0.79
LEU121 6.28 0.79
ASP124 4.35 0.79
TRP125 0.96 0.79
LEU127 0.14 0.79
THR128 -0.64 0.79
THR129 1.53 0.79
ASN130 0.24 0.79
THR131 -0.21 0.79
PHE134 1.84 0.79
ASN135 3.30 0.79
MET136 1.62 0.79
ARG137 23.84 0.81
THR138 -2.89 0.79
GLN139 0.29 0.79
ARG140 9.94 0.79
VAL141 2.65 0.79
GLN184 -1.55 0.79
ASN185 1.15 0.74
HIS186 0.14 0.79
LEU201 1.27 0.79
GLN202 -0.07 0.79
GLU203 10.37 0.72
ASP205 16.31 0.76
SER207 0.24 0.79
ASN210 -0.38 0.79
LYS218 11.13 0.79
Mutation G=kcal mol 1 err=kcal mol 1
LEU390 0.10 0.79
GLN391 0.41 0.79
GLU394 -13.16 0.79
PHE395 1.43 0.76
ARG396 21.04 0.79
ARG398 18.80 0.74
LYS399 23.07 0.84
LYS427 16.67 0.79
ASP431 -14.81 0.79
LEU433 0.50 0.79
THR434 6.09 0.79
VAL435 1.19 0.79
MET436 3.63 0.79
ASP437 -13.57 0.74
GLU474 7.91 0.79
GLU475 1.98 0.79
TYR477 6.31 0.79
LEU479 0.62 0.79
ASP480 17.56 0.79
LYS481 28.90 0.81
GLU483 0.79 0.79
PHE484 6.02 0.79
LEU485 0.55 0.79
SER487 -1.53 0.79
HIS488 1.15 0.79
GLU489 -4.44 0.76
ILE501 -0.45 0.79
PHE505 1.00 0.79
Table 3.1: Computational Alanine Scanning data with standard errors. Left column refers
to VP24 residues, right column to KPNA residues. Hot-spots are reported in bold.
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Figure 3.4: VP24 (blue)-KPNA (cyan) complex. The hot-spots arising from the CAS
analysis are highlighted in orange.
KPNA VP24
Figure 3.5: Left panel: Electrostatic potential of Karyopherin at the interface with VP24.
Values ranging from  kbT=e (red) e to +kbT=e (blue).
Right panel: Electrostatic potential of VP24 at the interface with Karyopherin. Values
ranging from  kbT=e (red) to +kbT=e (blue).
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Figure 3.6: Overview of the five salt bridges at the VP24-K interface.
aliphatic portion of the sidechain of Lys481’ has been also observed and is steadily
formed during the whole simulation (Figure 3.7).
Figure 3.7: The hydrophobic cluster at the VP24-KPNA interface.
Table 3.4 also shows the presence of some residues exhibiting a largely negative
G (i.e. residues whose mutation into alanine increase the binding energy between
the proteins). These are Glu88, Glu394’, Asp431’ and Asp437’. Inspecting the
electrostatic potential on VP24 and KPNA surface, it may be observed (Figure 3.8)
that all these negatively charged residues, when the complex is formed, actually
face a negative potential area on the binding partner. This suggest a somehow
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suboptimal affinity of VP24 for KPNA, which deserves further attention and should
be investigated by molecular biologists.
Figure 3.8: Left panel: Electrostatic potentials of Glu394’, Asp431’ and Asp 437’ (mesh
grid) facing VP24 interface (surface representation). Values ranging from  kbT=e (red) e
to +kbT=e (blue).
Right panel: Electrostatic potential of Glu88 (mesh grid) facing Karyopherin interface
(surface representation). Values ranging from  kbT=e (red) e to +kbT=e (blue).
3.4 Design of the RS peptide
Stemming from these geometric and energetic features of the VP24-KPNA inter-
face, we identified two KPNA segments comprising a set of hot-spot residues that
are close to one another not only in the protein tridimensional structure, but also
in its sequence. We inferred that a peptide sequence corresponding to one of these
KPNA subsequences could bind to VP24, thus interfering with VP24-KPNA com-
plex formation. The binding capability of an isolated peptide is not guaranteed
in principle, even if it contains several hot-spots, because it may undergo major
structural rearrangements when isolated from the parent protein and because of the
complexity of the interaction networks that lead to protein complex formation. The
first subsequence we considered, comprising the hot-spot residues Arg396’, Arg398’
and Lys399’, ranges from Ala393’ to Glu400’. A 100ns MD simulation of this pep-
tide in complex with VP24 shows large conformational fluctuations (Figure 3.10),
leading to a partial detachment of the peptide from the protein. In particular, the
salt bridge interactions involving the former hot-spots are completely lost. For these
reasons the peptide seems unable to interact with VP24, thus it was not further con-
sidered.
The second subsequence comprises residues ranging from Glu474’ to Phe484’. A
100 ns MD simulation and a CAS of the peptide-VP24 complex were performed
in order to evaluate the binding capability of the selected sequence. Both Glu474’
(hot-spot in VP24-KPNA complex) and Glu475’ show negative G values (Table
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Mutation G=kcal mol
 1
VP24-KPNA VP24-Glu474’ Phe484
GLU474 7.91 -2.13
GLU475 1.98 -6.26
TYR477 6.31 6.57
LEU479 0.62 0.43
ASP480 17.56 19.34
LYS481 28.90 27.60
ILE482 - -0.1
GLU483 0.79 9.08
PHE484 6.02 8.70
Table 3.2: Comparison between the G values caluclated for VP24-KPNA complex and
for VP24-Glu474’ Phe484 complex.
3.2), while all the remaining hot-spots are conserved. Based on these results we de-
cided to shorten the sequence discarding Glu474’ and Glu475’, obtaining a peptide
with a smaller net charge (-1 instead of -3) and maintaining a very high density of
hot-spots, namely Tyr477’, Asp480’, Lys481’ and Phe484’.
The selected peptide (from now on named RS, Figure 3.9) involves residues rang-
ing from Ala476’ to Phe484’ and has the sequence AYGLDKIEF. The same protocol
applied in the two aforementioned subsequences was employed. We ran a 100 ns long
molecular dynamics simulations of the VP24–RS complex, in order to investigate
whether the identified peptide could retain its ability to bind to VP24, even when
extracted from its protein environment. In contrast to what happened for the two
former sequences, the protein-peptide complex showed a good structural stability
during the whole simulation, with protein binding site and peptide binding mode
well conserved (Figure 3.10). On the other hand, its helical secondary structure was
progressively relaxed and eventually lost during the simulation (Figure 3.11).
Figure 3.9: Structure of the RS peptide.
Subsequently, a CAS was carried out in order to verify if the previously identi-
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Figure 3.10: RMSD versus time for VP24-K complex C atoms considering the crystal
structure as reference.
Figure 3.11: The RS peptide in complex with VP24. In the left panel the starting complex
structure is shown, in the right panel the VP24-RS structure after MD simulation. RS,
while keeping its interaction with the protein, loses its helical shape.
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Mutation G=kcal mol 1 =kcal mol 1
TYR477 7.68 0.60
LEU479 0.76 0.60
ASP480 18.28 0.57
LYS481 19.71 0.60
ILE482 1.67 0.62
GLU483 10.67 0.55
PHE484 6.99 0.60
Table 3.3: G values caluclated for VP24-RS complex.
fied KPNA hot-spots were conserved also in the VP24-RS complex. As shown in
Figure 3.12 and in Table 3.3, not only all the hot-spots are conserved, but also a new
one, i.e. Glu483’, can be identified. This residue forms a salt bridge with Arg137
which is observed in 90% of the trajectory of the VP24-RS complex. Interestingly,
this salt bridge, albeit present also in the VP24-KPNA complex, was observed only
in 31% of the trajectory.
Figure 3.12: Computational Alanine Scanning results for residues ranging from Tyr 477’
to Phe 484’ belonging to Karyopherin (blue bars) or to the RS peptide (red bars).
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3.5 Experimental evidences: NMR and CD
3.5.1 NMR
In order to experimentally verify if RS can actually bind VP24 in solution, NMR
experiments were performed. First, the capped-peptide was analyzed in terms of
conformational features by NOESY (500ms) and ROESY (200ms), observing no
medium and long-range correlations. Only sequential correlations could be found, in-
dicating that the peptide exists in random conformation. tr-NOESY and tr-ROESY
experiments showed no definite secondary structure in the peptide even upon ad-
dition of VP24. These observations mirror the behavior of RS in MD simulations,
both alone and in complex with VP24 (Figure 3.11). In this work, STD technique
was used as an epitope mapping device to describe the VP24-peptide interactions.
The method is based on the transfer of saturation from the protein to the bound
peptide which in turn, by exchange, is moved into solution where it is detected.
During the period of saturation, the magnetization gradually moves from the pro-
tein to the protons of the peptide when the ligand binds to the target. For transient
interactions with rapid exchange [99], the ligand polarization in the bound state is
transferred to the free state where the saturation accumulates during the irradia-
tion time of the experiment. The STD spectrum shows only the signals of peptide
protons that were in close contact with the protein (Figure 3.13).
Figure 3.14 shows the absolute STD percentage (grouped in two intensity ranges)
for protons which forms the epitope that reflects the relative proximity of the atoms
to the binding site. In fact, the ligand protons nearest to the protein are most likely
to be saturated to the highest degree, and therefore have the strongest signal in
the mono-dimensional STD spectrum. In particular, the more strictly interacting
moieties are the aromatic protons of Tyr477’ and Phe484’ (1.5 and 1.6 % absolute
STD respectively), the amidic proton of Asp480’ (2 % absolute STD) and the C-
terminal amide protons (1.6 % absolute STD). Although CAS analysis and STD
point out different aspect of peptide protein interaction (CAS is focused on the
energetic of side chain interactions highlighted by their mutation into alanine, while
STD supplies information on the proximity of a set of hydrogen atoms of the peptides
with respect to the protein) we may notice that, by and large, the two approaches
give mutually compatible and sound results.
The key role of the aromatic residues Tyr477’ and Phe484’, which take part in
hydrophobic interactions with VP24, are highlighted both by CAS and by NMR
analysis. Moreover, the role of charged residues, in particular Lys481’ and Asp480’,
while somehow overestimated by CAS, as often reported in literature [15], has been
observed by STD analysis. In order to perform a negative control, we analyzed the
linear octapeptide A (LGYGFVNY) in presence of VP24 protein by STD exper-
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Figure 3.13: Upper panel: selected regions of1H-NMR spectrum of 1.1 mM peptide in the
presence of 22 M VP24 protein in phosphate buffer, resulting in a 50:1 ligand-target ratio.
The signal labeled with an asterisk is due to the Lys, Leu and Ile amide protons which
show the same chemical shift. Bottom panel: The same region of the STD spectrum.
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Figure 3.14: Absolute STD% values, grouped in two intensity ranges, for peptide interact-
ing with VP24 toxins. The NH-amides of Leu, Lys and Ile, labeled with an asterisk, show
the same chemical shift.
iment. The A peptide has six residues in common with peptide RS, nevertheless
no interaction with the protein is observed. The observation that RS can actually
form a complex with VP24 in solution and the overall agreement between NMR and
computational data, support our initial hypothesis that the selected peptide could
bind to VP24 and suggest the plausibility of the proposed binding site.
3.5.2 Circular Dichroism
As a further confirmation of the interaction between RS and VP 24, far-UV circular
dichroism (CD) experiments were performed. This technique is, indeed, particularly
useful for studying protein folding and interactions [100]. In 50 mM PBS at pH
7.4, RS peptide failed to adopt an ordered conformation, exhibiting a random coil
structure (Figure 3.15, red line). In the same condition, VP24 is characterized by
two negative bands at 210 and 225 nm (amide n!  transition), that are typical of
-helix (Figure 3.15, black line). On the other hand, the absence of a positive band
below 200 nm (amide  !  transition) indicated that VP24 is present in solution
as a mixture different conformations. VP24-RS interaction was then evaluated. A
solution containing a mixture of RS and VP24 in 50 mM PBS was incubated at
room temperature and then CD spectrum was recorded. A comparison between the
spectrum of experimental mixture (Figure 3.15, blue line) and the arithmetic sum of
the two separated components (Figure 3.15, green line) highlighted that, actually, an
interaction occurred. Furthermore, the decrease in intensity of the negative Cotton
effects at 210 and 225 nm in the experimental mixture indicated a loss of the helical
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content of the protein, upon this interaction.
Figure 3.15: CD spectra of VP24 (black line), of peptide RS (red line), and of VP24/RS
experimental mixture (blue line). The green line is the arithmetic sum of VP24 and RS
single spectra.
3.6 Stapled peptides
As confirmed by CD and MD simulations, the RS peptide is unstructured, showing
no secondary structure features. However, when inserted in parent protein KPNA,
RS peptide exhibit an -helical structure (Figure 3.11), that could play an impor-
tant role in the interaction with VP24. For this purpose, starting from its original
sequence, we designed two stapled peptides. The term stapling refers to bond cova-
lently the sidechains of two amino acids to permanently reinforce a particular cyclic
restricted structure. This gives the peptide enhanced biophysical properties, such
as conformational stability and specificity for their biological target [101].
In Table 3.4 the sequences of the stapled peptides are shown. To build Mork pep-
tide we replaced Gly478’ and Ile482’ with an aspartate and an ornitine respectively,
while for Mindy we analogously substituted Leu479’ and Glu483’. As can be no-
ticed, the replaced residues are in position i, i+4. Moreover we capped the peptides
with an acetyl group (ACE) and a NH2 (NHE). Ornitine and aspartate sidechains
were bound with an amidic bond as shown in Figure 3.16.
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RS Mork Mindy
ACE ACE ACE
ALA ALA ALA
TYR TYR TYR
GLY GLY ORC
LEU ORC LEU
ASP ASP ASP
LYS LYS LYS
ILE ILE ASC
GLU ASC GLU
PHE PHE PHE
NHE NHE NHE
Table 3.4: Peptides sequences. In bold we have the
two residues whose sidechains are linked through
an amidic bond. ORC denotes an ornitine while
ASC is an aspartate.
Figure 3.16: In cartoon represen-
tation the backbone of Mindy. In
licorice the stapling. The aspartate
and ornitine are bound through and
amidic bond.
In order to assay the ability of the stapled peptides to maintain their secondary
structure features with respect to RS, we performed a 100ns molecular dynamics
simulation of Mork and Mindy in water monitoring their secondary structure. RS
and Mork compleately lose their alpha helical character (Figures 3.17, 3.18), show-
ing respectively no secodary structure and turn structure. This may be due to the
fact that the Mork stapling involves the substitution of Glu483’, with an aspartate.
As shown in Section 3.4, Glu483’ becomes an hot-spot when the peptide is extracted
from KPNA (Figure 3.12). This substitution can affect its ability to recover its he-
lical structure. On the other hand Mindy initially retains its alpha helical structure
(residues ranging from Gly478’ to Glu483’) but after a few nanoseconds the peptide
gains a 310 helical structure. 310 helix differs in its hydrogen bonds pattern from
the -helix: the carbonyl-amide hydrogen bonds are between residues i and i+3 in
the former and between residues i and i+4 in the latter. Moreover 310 helices have
been proposed to be intermediates in the folding/unfolding of -helices [102].
3.7 Conclusions
In this work we analyzed at the atomic level the network of interactions responsible
for the formation of the VP24-KPNA complex. The protein-protein interface has
been characterized, identifying the hot-spots residues, that give a major contribu-
tion to binding energy. From this analysis, a nonapeptide ranging from Ala476’ to
Phe484’ and comprising four hot-spots close to one another both in the tertiary and
primary structure ok KPNA has been identified. The ability of the selected peptide
to actually interact with VP24 has been assayed with Saturation Transfer Difference
NMR, which allowed to map the interaction epitope by determining the peptide re-
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Figure 3.17: Secondary structure analysis for the RS peptide. The colour code represents
the belonging of residues to a certain type of secondary structure.
White: no secondary structure. Pink: alpha helix. Green: turn region. Blue: 310 helix.
Mork Mindy
Figure 3.18: Secondary structure analysis of the stapled peptides. In the left panel Mork
peptide didn’t show an helical secondary structure, the cyan colour indentify a turn region
indeed. On the right panel Mindy peptide loses its alpha-helical structure at the beginning
of the dynamics (pink region) and gains a 310 helical structure (blue region).
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gions in contact with the protein receptor. On the whole, the epitope sketched by
NMR is consistent with the binding mode proposed by molecular modeling. The
interaction between the selected RS peptide and VP24 was assessed also by far-UV
CD experiments. Finally, we designed two stapled peptides in order to stabilize
RS helical secondary structure even when extracted from its protein environment.
One of them, Mindy, partially succeed in this task, showing a 310 helical structure
during most of the dynamics. VP24 is a potential target to reduce Ebola virulence
and lethality, but its structure, lacking well defined pockets and grooves is far from
being easily druggable. The identification of the RS peptide, which interacts with
VP24 through its surface, can be a useful starting point for further development of
VP24 targeting active molecules.
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Chapter 4
VP24 Pocket analysis and virtual
screening
4.1 The importance of pockets in proteins
Nowadays, a large amount of proteins molecular structures are available, due to the
advances in experimental (X rays and NMR) and computational methodologies, in
hardware and instrumentation [103]. In computational chemistry it is quite common
to use protein structure as a starting point for the drug design. In particular, most
of the drugs that target disease-related proteins binds in a site usually located inside
a concave pocket which allows the ligand to make many favorable contacts with the
target protein [104]. The crystal structures of protein-protein complexes, however,
often lack deep pockets or clefts at the interface region. The surface at the protein-
protein interface is, indeed, wide and almost flat. Therefore the structure-based
design of potential proteins inhibitors is considered quite difficult. Moreover, using
a static structure for the design of a potential inhibitor is often rather inadequate.
First of all, the structure of a protein depends to some extent on its environment,
so its structure in the crystal and in solution can show significant differences, in
particular concerning solvent exposed loops [105]. Second, the geometry of the
binding site in the holo-structures can be biased by the presence of the drug itself.
This can favour the binding of ligands with steric properties similar to the co-
crystallized inhibitor [106]. Finally, the crystal structures represent a conformation
averaged on thermal fluctuations. [107]. So the actual dynamics of the protein itself
has to be considered while designing a potential binder. The variability of the protein
structure can be taken into account using a large number of snapshots taken from
a molecular dynamics simulation. Moreover, this could allow the identification of
transient pockets that may not be present in the crystallographic structures. Because
there are strong evidences for the high plasticity of protein surfaces [108], we can
assume that transient pockets that are large and deep enough to bind small-molecule
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inhibitors may open from time to time. It has been shown that this happens on the
nanoseconds time scale, which is accessible with MD simulations [107,109]
4.2 Aim of the work
As discussed in Section 3.1 blocking the interaction between VP24 and Karyopherin
could be a good therapeutic strategy to reduce Ebola virulence. One possible way
to inhibit the formation of the protein-protein complex is to design a small molecule
able to bind on the surface of interaction between VP24 and KPNA. This can be
done exploiting the formation of transient pockets on the surface of VP24. Starting
from the crystallographic structure we carried out a pocket analysis of VP24 using
MD simulations in different solvents, in order to identify the best pocket in terms
of volume, polarity and position.
During the last two decades, plenty of computational methods have been devel-
oped in order to predict the position, shape, and interaction properties of a lig-
and binding pockets starting from protein structures [110, 111]. In this work we
employ the EPOSBP (Ensemble of Pockets on Protein Surfaces with BALLPass)
software in which the PASS [112] (Putative Active Sites with Spheres) algorithm
is re-implemented using the BALL [113] (Biochemical Algorithms Library) library.
This software allows us to identify also dynamic pockets and analyze their proper-
ties, such as relative frequency, and their average, minimum and maximum pocket
properties, namely volume, polarity, and depth. Now we will discuss, more in detail,
the geometrical basis of the PASS algorithm.
PASS PASS algorithm is designed to fill cavities in a protein structure with a set
of spheres located at the centers of binding pockets. Initially a coating of probe
spheres is calculated with the protein as substrate, then additional layers of probes
are placed onto the previously found probe spheres. Only probes with low solvent
exposure are retained and the routine finishes when an accretion layer produces no
new buried probe spheres. This is a purely geometrical algorithm. Different steps
of the algorithm are showed in Figure 4.1.
Once the best pocket has been identified, we performed a virtual screening (Sub-
section 1.8.2) of a database of known compounds to asses their ability to bind VP24
thus inhibiting its interaction with KPNA.
4.3 Computational details
Molecular dynamics VP24 crystallographic structure was obtained from the
complex VP24-KPNA deposited in the Protein Data Bank (PDB ID: 4U2X [82]).
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Figure 4.1: PASS algorithm. (a) PASS uses three-point geometry to coat the protein with
an initial layer of spherical probes. (b) These probes are filtered to eliminate those that
(i) clash with the protein, (ii) are not sufficiently buried, and (iii) lie within 1 Å of a more
buried probe. (c) A new layer of spheres (white) is accreted onto a scaffold consisting of
all previously identified probes (shaded). (d) The probes are filtered as described in step
b. (e) Accrete a new layer of spheres onto the existing probes, as in step c. (f) Accretion
and filtering (steps e and d) are repeated until a layer is encountered in which no newly
found probes survive the filters. This leaves the final set of probe spheres. (g) Probe
weights (PW) are computed for each sphere and active site points (ASPs) are identified
from amongst the final probes. (h) The final PASS visualization is produced. By default,
the final probe spheres are first smoothed, leaving only clusters of four or more. Image
taken from Ref [112].
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The residues numbers used here are referred to this structure. Molecular dynamics
simulations were carried out using GROMACS 4.5.3 [19] package using explicit sol-
vent (TIP4P water [94]) and periodic boundary conditions. AMBER99SB-ildn [68]
force field was used. The overall charge of the systems was neutralized with Cl 
or Na+ ions. The LINCS algorithm [4] was employed to constraint all bonds to
their equilibrium length, allowing a time step of 2 fs. The system was submitted to
10000 steps of geometry optimization with the steepest descent method. Afterwards
it was equilibrated for 200 ps in NVT conditions (T=300 K) and subsequently for
200 ps in NPT conditions, in order to equilibrate systems density. The cosolvents
(methanol and 2-methyl-2-propanol) were parametrized using the Generalized Am-
ber Force Field [69]. The productive phase of MD was performed in NPT conditions
(1 bar, T=300 K). Temperature and pressure were kept constant at their reference
value using the velocity rescale algorithm [71] and the Berendsen barostat [72], re-
spectively. A 14 Å cutoff was applied for non-bonded interactions and the Particles
Mesh Ewald algorithm [73] was employed to calculate long range electrostatic inter-
actions. The cluster analysis was carried out with the utility g_cluster using the
GROMOS clustering method [114].
Pockets identification and virtual screening The EPOS software was em-
ployed for identification of the pockets on the protein surface. The system was set
up for the virtual screening using Chimera Dock Prep tool [115]. This tool deletes
solvent and ions, adds missing hydrogens and adds charges to the system, using the
Amber force field [3]. DOCK6 spheres of radius between 1.4 and 4.0 Å were used to
map the chosen pocket, centered on residue Leu201. In order to describe the pocket
we selected spheres at a maximum distance of 5.5 Å from Leu201. Ligands were
taken from the ZINC database [116]. Docking calculations were carried out with
DOCK6 [45] using the Grid Score scoring function, using a grid of spacing 0.4 Å.
4.4 Pocket analysis
4.4.1 Crystallographic structure
Starting from the crystallographic structure of VP24 we performed a pocket analysis
using the EPOS software. The 7 pockets identified are listed in Table 4.1. Two of
them, labelled with Q and Y, attracted our attention because they are located at
the interface with KPNA (Figure 4.2). Moreover, they have the largest volume
compared to the others.
 Residues involved in Y pocket: 86 92 127 128 185 186 201 202 203 204 216 217
218.
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PID Volume / Å3 Polarity Depth / Å
Y 444.520 0.351 7.427
Q 648.177 0.354 3.848
2 247.232 0.304 7.077
3 305.199 0.385 5.496
4 532.360 0.343 6.558
5 338.725 0.351 7.462
6 385.095 0.365 8.184
Table 4.1: 7 pockets found in the crystallographic structure.
A B
Figure 4.2: A panel: The 7 pockets identified for VP24 crystallographic structure.
B panel: The Y pocket (highlighted in green) and the Q pocket (highlighted in orange).
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 Residues involved in Q pocket: 99 100 103 107 109 110 111 113 116 117 119
120 121 123 124 127 128 137 138 140 181 183 185 186 188.
These are static pockets, obtained from the analysis of the crystallographic structure.
As we are interested in the evolution of the protein structure and of pocket shape
and properties with time we performed a MD simulation in water and in more apolar
solvents: methanol and 2-methyl-2-propanol.
4.4.2 MD in water
We performed a 100 ns molecular dynamics simulation, in order to obtain a statisti-
cal ensemble of conformations to evaluate how shape and properties of the Q and Y
pockets change during the MD and to evaluate the formation of possible transient
pockets. We extracted 10000 frames from the trajectory and we performed a clus-
ter analysis using the GROMOS method with a 0.1 nm cutoff on the C RMSD,
obtaining 24 clusters. We analysed only the central structure of each cluster. Unfor-
tunately we didn’t identify any transient pocket. Anyway we analyzed the variation
in volume, depth and polarity of the Q and Y pockets. These informations are col-
lected in Table 4.2. Y and Q pockets are present during alomost the whole dynamics,
maintaining a quite large mean volume and depth.
4.4.3 MD in methanol and 2-methyl-2-propanol
To asses the stability of Q and Y pockets in more apolar solvents and further try to
identify transient pockets, we performed two 100 ns MD simulations in methanol and
in a 1M water solution of 2-methyl-2-propanol. This was done to mimic the dynamic
of the interface of VP24 in complex with KPNA, as the protein-protein interaction
surface is usually apolar. We extracted 10000 frames from each trajectory and
we performed a cluster analysis using the GROMOS method with a 0.1 nm cutoff
obtaining 31 clusters for methanol and 10 clusters for the 1M solution of 2-methyl-
2-propanol. We analysed the central structures of all the clusters but we didn’t
identify any interesting transient pocket. We then monitored the properties of the
pockets Q and Y (Table 4.2). Again, both pockets can be identified in the vast
majority of structures.
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Unfortunately this pocket analysis didn’t lead to the identification of any tran-
sient pockets suitable for virtual screening. Anyway we found out that both Q and
Y pocket are conserved during the dynamics, in water and in more apolar solvents.
Based on this results we decided to use the crystallographic Y pocket (present in
the 100% of the dynamics) as the binding site for a virtual screening.
4.5 Virtual Screening
4.5.1 Database choice
With our computational resources we are able to perform the docking of a maximum
of 500k compounds. Knowing this limitation we decided to select some subcategories
of the ZINC database. We started docking Natural products databases, comprising:
AfroDb Natural Products, AnalytiCon Discovery NP, IBScreen NP, Indofine Natu-
ral Products, Specs Natural Products, UEFS Natural Products and TCM Database
@ Taiwan. Then we moved to ZINC Purchasable databases, in particular: 3B Scien-
tific Corporation, BioBlocks BB, ChemDiv BuildingBlocks, Sigma Aldrich (Building
Blocks). Finally we docked the database Edrugs-3D, that contains FDA (Food &
Drug administration) approved drugs and active metabolites. The docking was per-
formed with DOCK6 using the Grid score scoring function for the energy evaluation.
We a priori discarded molecules with a MW < 150 g mol 1 and MW > 500 g mol 1
and with a formal charge greater than +4 and lower than -4. To analyze the docked
structures we used an energetic criterion, selecting molecules with at least a 2.5
kcal mol 1 binding energy per heavy atom. Moreover we discarded molecules with
more than 15% of electrostatic contribution to the overall energy.
4.5.2 Docking results
3B Scientific Corporation The database has more than 74000 molecules. The
molecular docking led to the identification of two major classes of compounds,
showed in panels A and B of Figure 4.3. Compound in Panel A is a triazine with
three substituents pointing towards different direction within the binding site of
VP24. Panel B compound is called olopatine and it is sold as a prescription eye
drop. The binding energy of both compounds is around  50 kcal mol 1.
AfroDb Natural Products The database contains 954 compounds. Among the
docked compounds only one met the filter criteria in this database. It is shown in
Panel C in Figure 4.3. The binding energy of this compound is  42 kcal mol 1.
69
AnalytiCon Discovery NP The database has 5154 molecules. Only one docked
compound met the filter criteria and it is shown in Panel D of Figure 4.3. This
compound is called haematoxylin, it is used as a stain and has a binding energy of
 41 kcal mol 1. The polycyclic motif is similar to the one found in the database
3B Scientific Corporation (Panel B).
BioBlocks BB This database contains 5840 compounds. Three molecules met
the filter criteria we applied. All of them have the same polycyclic structure as the
one shown in Panel E of Figure 4.3. The binding energy is around  43 kcal mol 1.
ChemDiv BuildingBlock The database has 25952 molecules. From the docking
results analysis we obtained only one compound that met the filter criteria and it is
shown in Panel F of Figure 4.3. The binding energy is  41 kcal mol 1.
Edrugs-3D The dataset has 1632 molecules. The most interesting molecules aris-
ing from the docking calculations are tioconazole, econazole (Panel G and H in
Figure 4.3) and other molecules with similar structure. These molecules are used
as antifungal medications and belong to the imidazole class. The average binding
energy is around  38 kcal mol 1. Moreover also olopatadine, already emerging from
the analysis of database 3B Scientific Corporation (Panel B), was found among the
best molecules for this database.
IBScreen NP The database has 84215 molecules. We observed two major classes
of molecules. The first class comprise molecules similar to the one showed in Panel I
of Figure 4.3. The binding energy is lower compared to the other selected molecules,
 47 kcal mol 1. The second class has polycyclic compounds with various sub-
stituents (Panel E) similar to the ones found in the BioBlocks BB database. Also
from the energetic point of view we obtain similar energies, around  43 kcal mol 1.
Sigma Aldrich (Building Blocks) The database contains 41718 compounds.
Interestingly, the most intresting compounds result to be the same antifungal molecules
we found in Edrugs-3D database (Panel G and H in Figure 4.3).
Specs Natural Products, TCM Database @ Taiwan, UEFS Natural Prod-
ucts These databases contain respectively 1489, 36043 and 473 molecules. After
the application of filters we didn’t find any molecule that met the filter criteria.
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A B C
D E F
G H I
Figure 4.3: Representative compounds arising from the analysis and selection of the virtual
screening results.
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4.5.3 Discussion
Dealing with the analysis of a huge amount of data is not easy, and we had to choose
a criterion to filter all the docked structure coming from the virtual screening. We
already decided to filter the compounds in input on the basis of the MW. We kept
molecules with 150g mol 1 < MW < 500g mol 1 and with a formal charge between
-4 and +4. To filter the molecules arising form the docking calculations we used
an energetic criterion, based on the energy per heavy atom: we decided to keep
molecules with a binding energy of 2.5 kcal mol 1 per heavy atom or more. Finally
we discarded compounds with an electrostatic contribution to the overall energy of
15% or more. As we can see from Figure 4.3 the majority of the selected compounds
are polycyclic (Panels B C D E F I), and some of them appear to be very similar
(Panel B and D). Moreover the analysis on two different databases (Sigma Aldrich
(Building Blocks) and Edrugs-3D) led to the identification of the same class of
compounds: the antifungals tioconazole and econazole. Evenly, the analysis of both
3B Scientific Corporation and Edrugs-3D databases identified the same compound:
olopatadine (Panel B). The three non-polycyclic compounds (Panels A G H) have
a feature in common: all three of them have three substituents pointed towards
different directions within the binding site of VP24, as shown in Figure 4.4.
Figure 4.4: VP24 in complex with the docking poses of tioconazole (green), econazole
(cyan) and triazine based compound (orange)
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4.6 Conclusions
In this study we carried out a pocket analysis on VP24 and we monitored their evolu-
tion in time. We identified a small number of compounds that could be able to bind
at the interface with KPNA. The pocket analysis on the crystallographic structure
highlighted the presence of two interesting pockets at the interface VP24-KPNA:
Q and Y pockets. Properties of these pockets were studied with MD simulations
in water and in two more apolar solvents, showing that the pockets are conserved
during the whole dynamics. Unfortunately MD didn’t highlight the presence of any
transient pocket. Crystallographic Y pocket was then chosen as the binding site for
a virtual screening on approximately 250k molecules. The Virtual screening results
were finally filtered with an energetic criterion and led to the identification of a
small number of compounds. These compounds have to be assayed biologically in
order to test if they are able to inhibit the formation of the protein-protein complex
VP24-KPNA.
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Chapter 5
VP24 behavior in presence of
osmoprotectants
5.1 Osmolytes
Osmolytes are solutes able to affect cell osmosis. In nature there are plenty of
strategies in order to allow plants and animals to survive in severe conditions, such
as high pressures and temperatures or high salinity. One of them is the accumula-
tion of highly soluble molecules, able to reduce osmotic stress of the cells, in cellular
fluids. A well known example is the resurrection plant (Figure 5.1) which is able to
“die” in the dry season and "resurrect" in the rainy one [117,118].
Figure 5.1: The resurrection plant, Selaginella lepidophylla. 1
Many different small organic molecules are known to serve as osmolytes. They
can be grouped in a few major chemical categories: small carbohydrates including
sugars (trehalose), polyols (glycerol, inositols, sorbitol, etc.) and derivatives (such as
o-methyl-inositol); amino acids (glycine, proline, taurine, etc.) and derivatives (e.g.
1Image taken from: http://www.sketchstationery.com/
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ectoine); methylamines (such as N-trimethylamine oxide (TMAO) and glycine be-
taine) and methylsulfonium solutes including dimethylsulfonopropionate (DMSP);
and urea. [119, 120]. In addition to their ability to control cell water loss or gain,
some osmolytes are also able to stabilize the native, folded structure of proteins
against either thermal or chemical denaturation [121]. These osmolytes are called
osmoprotectants or compatible solutes due to the high concentration they can reach
in living organisms without toxic effects. On the other hand, other osmolytes such
as urea, stabilize the unfolded structure of proteins and they are called denaturants.
Regardless the protein, the stability of the folded/unfolded state is linearly depen-
dent on the concentration of osmolyte/denaturant [122].
Besides their biological functions, osmoprotectants play an important role in differ-
ent fields:
 Agriculture: Plants able to synthesize this kind of compounds could be more
drought resistant and able to survive with less water for irrigation.
 Cosmetics: The introduction of osmoprotectants in creams can bring many
benefits. For instance epithelial cells will be less likely to undergo dehydration
phenomena.
 Ophthalmology: Osmoprotectants have recently found application in the treat-
ment of dry eye, to compensate extracellular hyperosmolarity without inter-
fering with cellular metabolic processes [123].
Although the diffusion of osmoprotectants in different fields, their effect on the
protein folded state is still unknown. There are different hypotheses that try to
rationalize the effect of osmoprotectants and denaturants. One ascribes the effect
of osmolytes to their interaction with the protein backbone, that varies the
stability of the protein itself [124–127]. The second hypothesis deals with the role
of the solvent. The water structure is weakened by denaturants, increasing the
solvation of the protein hydrophobic residues. Osmoprotectants strengthen water
hydrogen bond network leading to the opposite effect [128–131]. A third hypothesis
was proposed by Bolen [132]. In proteins native state the percentage of backbone
exposed to the solvent is lower with respect to the denatured state. Bolen purposes
an osmophobic effect, in which the driving force of the osmoprotection is the di-
rect, unfavorable interaction between osmoprotectants and protein backbone, which
leads to an exclusion of osmoprotectants from the protein domain. Osmoprotectants
destabilize both the native and the denaturated structure, however they destabilize
more the denaturated one, because it exposes more backbone residues.
In this chapter we study EBOV Viral Protein 24 in water and in presence of os-
molytes, in order to understand how they influence the protein structure. The choice
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of VP24 as a target was due to its clean circular dichroism spectrum. The effect of
osmoprotectants on the secondary structure of the protein can be easily seen by a
circular dichroism analysis. In this study we used urea (URE) as denaturant and
ectoine (ECT), glycine betaine (GBE), taurine (TAU) and trimethylamine N-oxide
(TMAO) as osmoprotectants. The osmolytes used in this work are shown in Figure
5.2. Analysis on the local solvent order, hydrogen bonds, diffusion coefficients were
carried out.
Ectoine (ECT) Glicine Betaine (GBE) Taurine (TAU)
Trimethylamine N-oxide
(TMAO) Urea (URE)
Figure 5.2: Molecular structures of osmolytes.
5.2 Computational details
The crystallographic structure of VP24 was obtained from the Protein Data Bank
(PDB ID: 4M0Q [133]). Six different systems were set up: VP24 in water and
VP24 in a 3 M solution of every osmolyte shown in Figure 5.2. Molecular dynamics
simulations were carried out with the GROMACS 4.5.3 [19] package using explicit
solvent and periodic boundary conditions. The AMBER99SB-ildn [68] force field
was used. Every system was solvatd with TIP4P [94] waters and neutralized with
Cl  or Na+ ions to reach neutrality. The choice of TIP4P water, which has a better
description of the electrostatic potential around the molecule, is due to the fact that
the aim of the work is to study solvent properties. The LINCS algorithm [4] was
employed to constraint all bonds to their equilibrium length, allowing a time step
of 2 fs. The system was submitted to 10000 steps of geometry optimization with
the steepest descent method. Afterwards it was equilibrated for 200 ps in NVT
conditions and subsequently for 200 ps in NPT conditions, in order to equilibrate
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systems density. Two sets of 50 ns molecular dynamics were performed in NPT
conditions, one at 300 K and the second at 330 K. Temperature and pressure were
kept constant at their reference value using the velocity rescale algorithm [71] and
the Berendsen barostat [72], respectively. A 14 Å cutoff was applied for non-bonded
interactions and the Particles Mesh Ewald algorithm [73] was employed to calculate
long range electrostatic interactions.
5.3 Results and Discussion
Molecular dynamics simulation of VP24 in water and in different solutions of os-
molytes were performed. A 3M concentration of osmolytes was used, and all the
dynamics were performed at two different temperature: 300 K and 330 K. In order
to understand how the presence of osmolytes influences the behavior of the protein,
general properties of VP24 were monitored for each simulation. In Table 5.1 water
self diffusion coefficients were computed using g_msd utility.
Solvent D / 10
 5cm2 s 1
300 K 330 K
H2O 3.74 6.33
Tau 3M 1.93 3.18
Ect 3M 0.94 1.86
Gbe 3M 1.37 2.46
Tmao 3M 1.75 3.30
Urea 3M 3.19 5.32
Table 5.1: Water self-diffusion coefficients for all the studied systems.
We can notice that all osmolytes reduce the water self-diffusion coefficients at
300 and 330 K. However, osmoprotectants dramatically reduce the self-diffusion
coefficients compared to denaturants such as urea. At 300 K the presence of ectoine
reduces the water self-diffusion coefficient by 75%. For urea the reduction is roughly
of the 15%. We can notice the same behavior at 330 K. Ordering the structure
of water (namely decreasing its diffusion coefficient) entails an entropic penalty for
water itself to act as primary denaturant, thus making the denaturation of the
protein more difficult even at high temperatures.
We can clearly see the effect of osmoprotectants on the order of water molecules
also from the analysis of the Radial Distribution Function (RDF) of water shown in
Figure 5.3.
The analysis was carried out at 300 and 330 K for all the systems studied. As
we can notice, all osmolytes induce an higher degree of order in water structure. In
particular osmoprotectants show an much higher RDF value with respect to water
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Figure 5.3: Radial distribution functions. We focus our analysis on the first peak of the
function.
and urea. Moreover the RDF peak of the systems simulated at 330 K is less intense,
due to the higher temperature that induces more kinetic energy in water molecules,
resulting in a more disordered structure.
The average number of hydrogen bonds between protein-osmolyte, protein-water and
osmolyte-water was calculated and the results are reported in Table 5.2. The average
number of hydrogen bonds between protein and urea is one order of magnitude
greater with respect to the osmoprotectants. This supports the hypothesis of urea
acting as backbone replacer. Urea, indeed, interacts more with the protein, leading
to a crowding of urea molecules in the proximity of the protein, as will be discussed
later. From Table 5.2 we can also notice that TMAO has the tendency to form less
hydrogen bonds compared to the other osmoprotectants; it has, indeed, only one
acceptor of hydrogen bond (Figure 5.2).
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The analysis on the preferential coefficient (Section 1.9) was carried out for the
systems at 300 K, the results are shown in Figure 5.4. The preferential coefficient
shows how many molecules of cosolvent are present at a certain distance from the
system, with respect to the bulk. If the preferential coefficient is lower than zero
it means that the cosolvent is excluded from the protein domain; this behavior is
verified for all the osmoprotectants. On the other hand if the value is greater than
zero, it shows a crowding of the cosolvent near the system, and this happens with
urea. This results support the osmophobic effect theory proposed by Bolen [132].
Figure 5.4: Preferential Coefficient
Finally the solvent density function was computed (Section 1.9). This function
describes how the molecules are distributed around the protein. It is, in principle,
equivalent to the radial distribution function, but it takes into account the shape
and the volume of the protein itself. The results are shown in Figure 5.5. The
absence, for all osmoprotectants, of a well-defined and prominent peak, shows that
they are excluded form the protein neighborhood. On the other hand, urea shows a
very intense peak supporting, once again, its tendency to act as a backbone replacer
and stabilize the denaturated state of the protein, which exposes more backbone.
5.4 Conclusions
In this work we studied the effect of osmolytes on VP24. The obtained values of
preferential coefficient and solvent density function show that osmoprotectants and
urea have opposite effects on the protein. Osmoprotectants are excluded from the
protein domain, while urea molecules crowd in the proximity of the protein. Both
these effects support the osmophobic effect theory [132]: the interaction between
the osmoprotectants and the protein backbone is unfavorable, so they are excluded
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Figure 5.5: Solvent density function
from the protein domain. Moreover the analysis on hydrogen bonds, RDF and
diffusion coefficients highlight how osmoprotectants can influence the order of the
solvent, namely increasing the degree of order of water. In this case osmoprotectants
prevent water to act as primary denaturant, ordering its structure.
In future Gunfolding of VP24 has to be calculated and circular dichroism analysis
on these system have to be performed, in order to asses the effect of osmolytes on
the unfolding temperature of VP24.
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Concluding remarks and future
perspectives
In this PhD thesis different inhibition strategies for Ebola virus have been explored,
targeting two of the seven viral protein coded by Ebola genome: VP24 and VP35.
The interaction between VP35 C-terminal interferon inhibitory domain and known
inhibitors of this protein is studied at the atomistic level in Chapter 2, highlighting
new important key interactions between the inhibitors and the protein. Essential
dynamics analysis pointed out an interesting closing motion that is characteristic
of the apo-form, and it is reduced in amplitude when the protein is bound to in-
hibitors. The functional role of these motions in the interaction with viral NP is not
clear yet. Recent literature [134,135] shows that the N-terminal domain of VP35 is
actually interacting with viral nucleoprotein. The collective motions highlighted in
this study can, therefore, play an relevant role at the allosteric level. This subject
deserves further attention from molecular biologist.
VP24 was studied in Chapters 3, 4 and 5.
Chapter 3 dealt with the study of VP24-KPNA protein-protein complex. A com-
putational alanine scanning allowed us to identify a KPNA subsequence with a high
density of hot-spots. A nonapeptide was designed starting from this sequence and its
ability to bind VP24 was tested both computationally and experimentally through
NMR and CD. It is largely known, however, that peptides are not the ideal can-
didates to inhibit protein protein interactions in vivo, due to their poor metabolic
stability and low bioavailability. Although, a peptide like this can serve as a start-
ing point for the design organic inhibitors sharing the same pharmacophore with
the peptide itself. Starting from the original sequence, stapled peptides were also
desiged, as they can be less prone to metabolic degradation and, moreover, one of
them maintains a 310 helical structure that could improve the binding to VP24. We
are, however, waiting for them to be synthesized, in order to test them on VP24
through NMR and CD.
InChapter 4 a pocket analysis on VP24 was carried out, which identified 2 interest-
ing pockets at the interface with KPNA. Geometric and physical properties of these
pockets were studied in different solvents through MD simulations, highlighting their
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presence during the whole MD. A subset of ZINC database was then docked into one
of these pockets and ranked through an energetic criterion using DOCK 6 scoring
function. This led to the identification of a small number of potential VP24 ligands.
It is known that DOCK scoring functions doesn’t provide an accurate estimate of
the binding energy however, due the large number of docked compounds (over 200k),
this scoring function was the only fast and accessible method to energetically rank
the compounds. For the most interesting molecules, more accurate analysis are in
progress, including MD simulations and subsequent MM-PBSA calculation of the
binding energies.
Chapter 5 dealt with the analysis of the folding stability of VP24 by explicit sol-
vent MD both in the presence and absence of osmolytes. The analysis of different
properties was carried out, including water self diffusion coefficient, water radial dis-
tribution function, average number of hydrogen bonds, preferential coefficient and
solvent density function. Based on these results it is clear how osmoprotectants and
urea have opposite effects on the protein, the former stabilizing the folded state and
the latter shifting the equilibrium to the denatured state. As a further development
experimental tests on melting temperature of VP24 in presence of these osmolytes
through CD have to be carried out.
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Part II
Coarse grain simulations of
antimicrobial peptides
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Chapter 6
Investigating SVS-1 pore formation
mechanism
6.1 Antimicrobial peptides
Antimicrobial peptides (AMPs) are widely distributed in nature, being produced
by mammals, birds, amphimians, insects, plants and microorganisms [136]. Al-
though they form a diverse group of peptides as judged by their primary structures,
they are often cationic and amphiphilic molecules with opposing hydrophobic and
policationic faces. Their mechanism of action entails the disruption of cancer cell
membranes. Indeed, during the apoptosis process the membrane undergoes both
biochemical and structural changes. The morphological modifications include cell
shrinkage, chromatin condensation, nuclear fragmentation and formation of dynamic
plasma membrane protrusions called blebs, which eventually detach, culminating in
fragmentation into apoptotic bodies [137]. From the biochemical point of view the
membrane lipid distribution in cancer cells is different from the one in normal cells.
Normal mammalian cells have an asymmetric lipid distribution of phospholipid type
between the two leaflets of the lipid bilayer. The outer leaflet contains mostly zwit-
terion lipids, displaying an overall neutral charge. The inner leaflet contains mainly
phosphatidylethanolamine and phosphatidylserine (PS), resulting in an overall neg-
ative charge [138, 139]. Loss of lipid asymmetry, due to translocation of PS in the
outer leaflet, is found to occur in a number of tumor cells, allowing this negatively
charged surface to be used as a target in cancer therapy (Figure 6.1). The cationic
face of AMPs is responsible for engaging the negatively charged surface of the can-
cer cell through hydrogen bonds and electrostatic interactions, the amphiphilic face
enables membrane permeabilization.
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Figure 6.1: Different lipid distribution in a normal cell membrane (upper panel) and
in a cancer cell membrane (bottom panel). PC: phosphatidylcholine. PE: phos-
phatidylethanolamine. PI: phosphatidylinositol. PS: phosphatidylserine. SM: Sphin-
gomyelin. Image taken from Ref [137].
6.2 SVS-1
Most of cationic AMPs are unstructured in solution and gain their secondary struc-
ture, usually helical, at the cell surface. The driving force of the folding is the
favorable interactions between the membrane surface and the peptide [140]. Even if
the biological active conformation of most anticancer AMPs is helical, there are few
that adopt a -structure. However, unlike helical peptides, these  rich AMPs are
folded prior to engaging the membrane.
In 2010 Schneider et al. reported, for the first time, the design of a peptide
(from now on called SVS-1) that folds in a bioactive -structure at the surface
of cancer cells, adopting an amphiphilic  hairpin structure capable of membrane
disruption [141].
SVS-1 is a 18 residues long peptide. Its sequence is:
KVKVKVKV DPLPTKVKVKVK  NH2
It contains N- and C- terminal strand regions of alternating valine and lysine residues
connected by a tetrapeptide ( V DPLPT ) designed to mimic the  turn of the 
hairpin structure. In solution the peptide adopts an ensemble of random coil con-
formations, where the turn region of the peptide is structured and the two strand
regions aren’t. In absence of any compensatory interactions, the high positive charge
density from lysine side chains results in intrastrand repulsion, making the C- and N-
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Figure 6.2: SVS-1 in solution adopts a random coil conformation. When it engages the
negatively charged membrane surface, SVS-1 folds into a bioactive,  hairpin conformation.
Image taken from Ref [141].
terminal strands interaction impossible. However, when SVS-1 encounters the nega-
tively charged surface of the cell membrane, the lysine rich face interacts with it, al-
lowing the terminal strands to collapse and form the -hairpin. This surface-induced
folding is made possible due the thermodynamic balance between the electrostatic
strand repulsion and the formation of favorable membrane-peptide ion pairs. In the
folded state SVS-1 should exhibit one lysine-rich face which engages the cell surface
and an opposing valine-rich hydrophobic face. Schneider et al. proved the folding
of the peptide on the membrane and showed that the peptide is able of disrupt-
ing the membrane integrity forming pores. However the mechanism of formation of
these pores is still unknown. During my stay in the group of Prof. S. J. Marrink
in University of Groningen I tried to elucidate this mechanism using a coarse grain
representation of the system.
6.3 Computational details
The Martini CG force field [6–8] version 2.2 ElNeDyn was employed to describe the
system at the coarse grain level. The ElNeDyn approach uses a global elastic network
between the backbone beads to conserve the conformation in proteins or peptides.
Molecular dynamics simulations were carried out with GROMACS 5.1.x package
[142]. All the membranes were built with the insane tool [143]. The martinize
tool was used to convert the peptide from the all atom representation to the coarse
grained one. Systems were solvated with polarizable water model. Ions were added
in order to reach the neutrality. Every system was submitted to 10000 steps of
geometry optimization with the steepest descent method. Then the systems have
been submitted to two different equilibration phases in NPT condition: the first one
with a time step of 10 fs for 15 ns, the second one with a time step of 20 fs for 30 ns.
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The production phase of the molecular dynamics was performed with a 20 fs time
step. Temperature and pressure were kept constant to their reference values using
the velocity rescale algorithm [71] and the Berendsen barostat respectively [72]. A
11 Å cutoff was applied for non-bonded interactions and the Particles Mesh Ewald
algorithm [73] was employed to calculate long range electrostatic interactions.
6.4 All atom simulation of SVS-1
The SVS-1 peptide was built with the Pymol build utility [144]. An all atom molec-
ular dynamics simulation in explicit solvent of 50 ns was performed on the peptide,
using distance restraints between the carbonyl and NH group of the backbone in
order to force a -hairpin conformation. This simulation was performed in order to
obtain a statistical ensemble of conformations of the SVS-1 peptide in the -hairpin
structure. At the very beginning of the dynamics (first few ns) the peptide assumes
the -hairpin conformation, as shown in Figure 6.3.
A B
Figure 6.3: A panel: Starting structure for the all atom dynamics of SVS-1 peptide.
B panel: One snapshot extracted from the MD simulation. The backbone in orange
cartoon representation, lysine residues in blue and valine residues in green.
Once the conformation was extracted from the MD simulation, we coarse grained
the peptide using the martinize tool.
6.5 Plain MD simulations
There are several choices of lipids in order to build up a negatively charged membrane
in Martini. As in the work of Schneider et al. [141], for the experimental tests they
used a POPS POPC 1:1 membrane, we used a membrane of the same composition.
The structures of the lipids are shown in Figure 6.4. The simulation box is 14x14x15
nm solvated with polarizable water model. We built two different systems composed
of the same membrane with different number of peptides adsorbed on it, that is:
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(a) POPC
(b) POPS
Figure 6.4: Structures of lipids composing the membrane.
 A low density peptide system, with 1/32 peptide/lipids (P/L) ratio.
 A high density peptide system, with 1/20 peptide/lipids ratio. (Figure 6.5)
A B
Figure 6.5: In orange SVS-1 peptides, in blue POPC and in red POPS. Waters are hidden
for sake of clarity. A panel: A view of the xy plane of the high density system.
B panel: A view of the xz plane of the high density system. As it can be seen peptides
are placed only on one side of the membrane.
Peptides were placed only on one side of the membrane because we want to
simulate the process of disruption of the membrane itself. What happens in vivo
indeed is that the antimicrobial peptides approach the membrane only from the
outer leaflet. We performed 7 s MD simulations for both systems, observing no
pore formation. In both systems the peptides stick to the membrane and diffuse
on it. The analysis of the depth of insertion of the peptides with a density plot
(Figure 6.6) shows that valine has a slightly higher depth of insertion than lysine,
as expected. Lysine residues, in fact, interact with the charged phosphate groups
on the surface of the membrane, while valine residues tend to interact more with
the GL beads located deeper in the membrane. We can also notice some differences
between the density plots of the two systems. Namely, in the 1/20 P/L system, we
observe two density peaks both for valine and lysine, which are missing in the 1/32
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P/L one. This means that there is no more space for the peptides to adsorb on the
membrane, so they dispose on two different layers.
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Figure 6.6: Density plot for phosphate groups (black), valine residues (red) and lysine
residues (green). In the 1/20 P/L system the peptides dispose themselves on two different
layers.
The number of contacts shows a clear preference for the peptides to interact with
POPS with respect to POPC (Figure 6.7). This is not surprising, as each peptide
bears a +8 charge and POPS has an anionic headgroup. If we look deeper in the
number of contacts and compute valine and lysine contacts separately we can see
that lysine interacts definitely more with the membrane than valine (Figure 6.8).
This, again, is due to the positive charge of lysine that interacts with the phosphate
group. This analysis shows the same results for both of the systems. For sake of
brevity only the results on the 1/32 P/L system are shown. The pore formation
could occur in a larger timescale that is not simulable in our case.
6.6 Induced pore formation
Considering that we don’t observe any pore formation during the MD simulation
and this could be due to kinetics, we decided to induce the pore formation in the
membrane using an inverted potential. This type of potential is implemented since
GROMACS 5.1 version and is shown in Figure 6.9. It is a type of flat-bottomed
potential, used to restrain particles to a particular part of the simulation volume.
No force acts on the restrained particles within the flat-bottomed region of the
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Figure 6.7: Number of conctats between peptides and the two different lipid types of the
membrane.
POPS POPC
Figure 6.8: Number of conctacts of valine and lysine residues with POPS (left panel) and
POPC (right panel).
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potential. When the restrained particles move out of the flat-bottomed region, a
harmonic force acts on them to move particles to the flat-bottomed region (eq. 6.1).
Vfb(~ri) =
1
2
kfb[dg(~ri; ~Ri)  rfb]2H[dg(~ri; ~Ri)  rfb] (6.1)
~Ri is the reference position, rfb is the distance from the center with a flat po-
tential, kfb is the force constant and H is the Heaviside step function. The distance
dg(~ri; ~Ri) from the reference position depends on the geometry of the flat-bottomed
potential. In GROMACS it is possible to invert the restrained region with the un-
restrained region, leading to a potential that acts to keep the particles outside the
defined volume (Figure 6.9, panel B). This inverted potential is shown in eq. 6.2.
V invfb (~ri) =
1
2
kfb[dg(~ri; ~Ri)  jrfbj]2H[dg(~ri; ~Ri)  jrfbj] (6.2)
Figure 6.9: Flat-bottomed and inverted potential implemented in GROMACS.
We selected a point in the center of the membrane and we applied a 1000
kJmol 1nm 1 repulsive potential acting on the GL beads of POPS and POPC.
We ran MD simulations on both the 1/20 and 1/32 P/L systems forming, for ev-
ery system, three pores of different dimensions: 3nm, 4nm and 5 nm. The MD
simulations were 7 s long for the 1/32 P/L system and 5.5 s long for the 1/20
P/L system. In this case the peptides are allowed to pass on the other side of the
membrane exceeding the pore itself. From the density analysis of peptides on xy
plane performed with the g_densmap utility we can notice that peptides density is
higher on the edge of the pores (Figure 6.10 and Figure 6.11). This happens for
both of the simulated systems and for all the pore dimensions. The peptides diffuse
on both sides of the membrane passing through the pore.
After a few s of sampling we selected some snapshots taken from different
systems and pore dimensions in which one or more peptides were positioned through
the pore and we removed the inverted potential creating the pore. In total we
simulated the potential removal in 10 systems. The typical starting structure is
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Pore 3nm Pore 4nm
Pore 5nm
Figure 6.10: Density plot of the peptides for the 1/32 P/L system in the xy plane. Peptides
density is higher on the edge of the pore.
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Pore 3nm Pore 4nm
Pore 5nm
Figure 6.11: Density plot of the peptides for the 1/20 P/L system in the xy plane. Peptides
density is higher on the edge of the pore.
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shown in Figure 6.12.
xy plane xz plane
Figure 6.12: The starting structure for the potential removal of one of the simulated
systems.
In the majority of the cases (7 out of 10) the pore closes in few tents of nanosec-
onds (20-40 ns). In 3 cases the pore closes but one peptide remains stuck through
the membrane, although it is spitted out after 1 s. The induced pore formation
seems not to help the peptide inserting through the membrane, moreover the pep-
tides that manage to stay into the membrane after the inverted potential removal
don’t succeed to remain inside the membrane itself.
6.7 Slow potential removal
Based on the results arising from the former dynamics we decided to try to remove
the inverted potential slowly, decreasing step by step its value from 1000 to 500,
200, 100, 0 kJmol 1nm 1 and performing short 100 ns long MD simulations for
each value of the potential. The pore remains in its position till the potential is
completed shut down. With no potential acting on lipids the pore slowly closes and
we obtain something very similar to what we observed in the Section 6.6.
6.8 Conclusions
It is clear from the MD results that these peptide are not able to form pores. One
of the reasons could be the intrinsic stability of the lipid bilayer in the MARTINI
force field. MARTINI, indeed, was originally created as a CG force field for lipids,
and the interactions among the apolar beads governing the formations of the bilayer
were tuned to form the bilayer itself.
We also tried to simulate a less thick membrane (DLPC/DLPS) but no pore for-
mation was observed. For sure, in order to simulate system bearing big charges like
these, polarizable water model and PME treatment of electrostatic interactions are
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strongly recommended. In our opinion a better parametrization of the electrostatic
interaction of the force field (Q beads) could improve the description of the mech-
anism of pore formation in MARTINI. Marrink et al. are already working on the
development of MARTINI 3.0 where reformulation of the Q-particles will be carried
out.
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E mentre succede tutto questo, chissà IlC...
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